[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 751
1. Pahlavan PS, Kanthan R: Goblet cell carcinoid of the appendix. World J Surg Oncol; 2005 Jun 20;3:36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Goblet cell carcinoid (GCC) of the appendix is a rare neoplasm that share histological features of both adenocarcinoma and carcinoid tumor.
  • While its malignant potential remains unclear, GCC's are more aggressive than conventional carcinoid.
  • The clinical presentations of this neoplasm are also varied.
  • The focus is on its diagnosis, histopathological aspects, clinical manifestations, and management.
  • Accurate diagnosis of this neoplasm requires astute observations within an acutely inflamed appendix as this neoplasm has a prominent pattern of submucosal growth and usually lacks the formation of a well-defined tumor mass.
  • The most common clinical presentations in order of frequency were acute appendicitis in 22.5%; asymptomatic in 5.4%; non-localized abdominal pain in 5.15% and an appendicular mass in 3.09%.
  • Concomitant distant metastasis at diagnosis was present in 11.16% of patients with the ovaries being the most common site in 3.60% followed by disseminated abdominal carcinomatosis in 1.03%.
  • Local lymph node involvement was seen in 8.76% of patients at the time of diagnosis.
  • GCC's of the appendix remains a neoplasm of unpredictable biological behavior and thus warrants lifelong surveillance for recurrence of the disease upon diagnosis and successful surgical extirpation.
  • CONCLUSION: GCC of the appendix is a rare neoplasm.
  • Due to its wide range of presentation, this tumor should be considered as a possible diagnosis in many varied situations leading to abdominal surgery.
  • Cytoreductive surgery with adjuvant intraperitoneal chemotherapy can offer improved survival in cases with advanced peritoneal dissemination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1987 Feb;30(2):112-5 [3803115.001]
  • [Cites] Cancer. 1974 Mar;33(3):770-7 [4815580.001]
  • [Cites] Cancer. 1974 Aug;34(2):338-44 [4852178.001]
  • [Cites] Cancer. 1979 Nov;44(5):1700-6 [498041.001]
  • [Cites] Pathol Res Pract. 1984 Jul;178(6):555-61 [6483683.001]
  • [Cites] Gastroenterology. 1984 Feb;86(2):302-9 [6690357.001]
  • [Cites] Hum Pathol. 1982 Mar;13(3):286-8 [7076213.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):188-9 [7102895.001]
  • [Cites] Acta Obstet Gynecol Scand. 1982;61(2):153-6 [7113691.001]
  • [Cites] Diagn Gynecol Obstet. 1980 Winter;2(4):269-74 [7215111.001]
  • [Cites] Am J Surg Pathol. 1981 Apr;5(3):213-24 [7235117.001]
  • [Cites] Cancer. 1978 Dec;42(6):2687-95 [728868.001]
  • [Cites] Cancer. 1978 Dec;42(6):2781-93 [728874.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;386(2):201-10 [7368563.001]
  • [Cites] Acta Morphol Acad Sci Hung. 1980;28(1-2):37-58 [7446221.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):869-70 [7490325.001]
  • [Cites] Diagn Cytopathol. 1995 Feb;12(1):59-61 [7789249.001]
  • [Cites] Intern Med. 1994 Jul;33(7):422-6 [7949643.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):685-7 [7978019.001]
  • [Cites] J Clin Pathol. 1977 May;30(5):473-80 [864014.001]
  • [Cites] Histopathology. 1995 Dec;27(6):557-62 [8838336.001]
  • [Cites] Int J Gynecol Pathol. 1996 Jan;15(1):85-8 [8852453.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):109-13 [8990147.001]
  • [Cites] Arch Pathol Lab Med. 1976 Jun;100(6):301-6 [946758.001]
  • [Cites] J Gastroenterol. 1998 Aug;33(4):582-7 [9719248.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):815-21; discussion 822-3 [10363895.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):14-21 [10391558.001]
  • [Cites] Eur J Surg. 1999 Oct;165(10):993-7 [10574110.001]
  • [Cites] Surg Today. 2000;30(1):78-81 [10648090.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):386-90 [11231488.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):557-68 [11342766.001]
  • [Cites] Pathol Int. 2001 Apr;51(4):283-7 [11350611.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2001 Jul;97(1):90-5 [11435017.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):140-6 [11884049.001]
  • [Cites] Endocr Pathol. 2002 Spring;13(1):47-58 [12114750.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3307-12 [12115365.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):551-64 [12163380.001]
  • [Cites] Dig Dis Sci. 2002 Dec;47(12):2760-2 [12498298.001]
  • [Cites] Histopathology. 2003 Feb;42(2):137-40 [12558745.001]
  • [Cites] Surg Today. 2003;33(5):375-8 [12734735.001]
  • [Cites] Radiographics. 2003 May-Jun;23(3):645-62 [12740466.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1317-22 [14598408.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1189-98 [14681318.001]
  • [Cites] Eur J Surg Oncol. 1992 Aug;18(4):386-7 [1521632.001]
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1168-73 [15449269.001]
  • [Cites] Diagn Cytopathol. 1991;7(2):155-7 [1648469.001]
  • [Cites] Histopathology. 1991 Jan;18(1):61-5 [1672861.001]
  • [Cites] Leber Magen Darm. 1991 Sep;21(5):226,229-30 [1758238.001]
  • [Cites] Br J Urol. 1976 Dec;48(6):436 [188508.001]
  • [Cites] Acta Pathol Jpn. 1991 Jun;41(6):455-60 [1950561.001]
  • [Cites] Am J Clin Pathol. 1990 Jul;94(1):27-35 [2163192.001]
  • [Cites] Arch Pathol Lab Med. 1979 Apr;103(4):180-2 [218519.001]
  • [Cites] Gut. 1990 Mar;31(3):322-4 [2323597.001]
  • [Cites] Gut. 1990 Jul;31(7):840 [2370022.001]
  • [Cites] Int Surg. 1989 Apr-Jun;74(2):109-10 [2753618.001]
  • [Cites] J Surg Oncol. 1988 Jan;37(1):65-71 [2826924.001]
  • [Cites] Arch Pathol Lab Med. 1985 Oct;109(10):930-3 [2994592.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1987;412(2):175-82 [3122418.001]
  • [Cites] Surg Gynecol Obstet. 1988 Jul;167(1):81-6 [3289135.001]
  • [Cites] Dis Colon Rectum. 1988 Aug;31(8):605-12 [3402286.001]
  • (PMID = 15967038.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1182398
  •  go-up   go-down


2. Gómez Portilla A: [Peritoneal carcinomatosis. Ten years of applying the new combined triple therapy. Personal experience]. Cir Esp; 2007 Dec;82(6):346-51
Genetic Alliance. consumer health - TEN.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal carcinomatosis. Ten years of applying the new combined triple therapy. Personal experience].
  • [Transliterated title] Carcinomatosis peritoneal. Diez años aplicando la nueva triple terapia combinada. Experiencia personal.
  • INTRODUCTION: Peritoneal carcinomatosis is the main problem in treating patients with advanced cancer; in addition to the lack demonstrably effective treatment, once diagnosed, this condition leads inexorably and rapidly to death.
  • There is no response to traditional systemic treatments and the mean survival is less than 12 months after diagnosis.
  • The application of a new combined triple therapy consisting of cytoreductive surgery together with perioperative intraperitoneal chemotherapy and heated intraoperative intraperitoneal chemotherapy followed by early post-operative intra-abdominal chemotherapy is providing good results, even occasionally with curative intent, which suggests a new alternative treatment strategy.
  • Long-term survival was achieved among patients treated for persistent diffuse carcinomatosis secondary to pseudomyxoma, ovarian carcinomatosis, primary malignant peritoneal mesotheliomas, and colon carcinomatosis.
  • In our experience, we were able to achieve an initial control of the disease in 83% of our patients, medium-term survival (3 years) in 20% and long-term survival in 12.5% in four of the disease entities included in our protocol for the treatment of carcinomatosis.
  • [MeSH-major] Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053504.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. Gómez-Portilla A, Cendoya I, López de Tejada I, Olabarria I, Magrach L, Martínez de Lecea C, Gil A, Valdovinos M, Larrabide I, Ruiz de Alegría N, Fernández JL, Cachorro I, Contreras Mdel C, Castañeda J, Uriarte A, Boado MV, Urturi JA, Ulibarrena MA: [Principles of the treatment of peritoneal carcinomatosis due to colorectal cancer. Current review and update]. Cir Esp; 2005 Jan;77(1):6-17
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Principles of the treatment of peritoneal carcinomatosis due to colorectal cancer. Current review and update].
  • [Transliterated title] Bases y fundamentos del tratamiento de la carcinomatosis peritoneal por cáncer colorrectal. Revisión actual y puesta al día.
  • The incidence of abdominal dissemination is high and all studies of the natural history of colorectal carcinomatosis demonstrate that prognosis in these patients is poor, with a mean survival of between 5 and 9 months.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / therapy. Colorectal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420876.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 100
  •  go-up   go-down


Advertisement
4. Muñoz Hernández A, Lorente Ramos R, Azpeitia Armán J, Grande Bárez M: [Peritoneal AA amyloidosis simulating peritoneal carcinomatosis: a case report]. Radiologia; 2010 Mar-Apr;52(2):162-6
MedlinePlus Health Information. consumer health - Peritoneal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal AA amyloidosis simulating peritoneal carcinomatosis: a case report].
  • [Transliterated title] Amiloidosis peritoneal AA. Presentación de un caso que simula carcinomatosis peritoneal.
  • We present the case of a patient with a history of Hashimoto's thyroiditis and systemic symptoms who presented with abdominal pain.
  • CT showed thickening of the wall of the colon with infiltration of the adjacent peritoneum and extension to the root of the mesentery with abundant ascites.
  • The histological diagnosis was peritoneal AA amyloidosis.
  • [MeSH-major] Amyloidosis / radiography. Carcinoma / radiography. Peritoneal Diseases / radiography. Peritoneal Neoplasms / radiography
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Serum Amyloid A Protein. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Amyloidosis AA.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 SERAM. Published by Elsevier Espana. All rights reserved.
  • (PMID = 20188389.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Serum Amyloid A Protein
  •  go-up   go-down


5. Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT: Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol; 2005 May;97(2):457-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
  • Widespread intra-abdominal carcinomatosis, which mimics metastatic ovarian serous carcinoma, has been reported following oophorectomy in individuals at increased hereditary risk.
  • This study was undertaken to examine and report particularly the occurrence of intra-abdominal carcinomatosis, as well as other cancers, following prophylactic oophorectomy in patients who carry cancer susceptibility mutations of BRCA1 and BRCA2 and to assess the cumulative risks for this disease in order to assist in developing appropriate surgical interventions, based on currently available information, and to counsel patients who choose prophylactic surgery, concerning the potential prognosis, thereafter.
  • All available histologic and cytologic materials of patients who were diagnosed with intra-abdominal carcinomatosis were reviewed, and life-table calculations were performed to assess cumulative risks for this disease following prophylactic oophorectomy.
  • During a mean follow-up of 9.3 years, cancers were diagnosed in 27 subjects, including 16 individuals with breast cancer and five patients with intra-abdominal carcinomatosis.
  • All five cases of intra-abdominal carcinomatosis were serous carcinomas, and all occurred in BRCA1 mutation carriers.
  • Two of the five patients who developed intra-abdominal carcinomatosis were among 78 patients in this series who were diagnosed and treated for breast cancer before prophylactic oophorectomy.
  • CONCLUSIONS: Intra-abdominal carcinomatosis in our series was diagnosed only in BRCA1 mutation carriers.
  • The calculated cumulative risks of developing intra-abdominal carcinomatosis after prophylactic oophorectomy in members of HBOC syndrome families, specifically those who carry deleterious mutations, are well below the estimated risks of ovarian cancer published in the literature for similar patients.
  • [MeSH-major] Abdominal Neoplasms / genetics. Breast Neoplasms / genetics. Carcinoma / genetics. Genes, BRCA1. Genes, BRCA2. Ovarian Neoplasms / prevention & control


6. Targnion A, Broze B, Habonimana E, Jouan H, Frémond B: [Gliomatosis peritonei, an unusual abdominal carcinomatosis: report of two cases]. Arch Pediatr; 2010 Aug;17(8):1169-73
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gliomatosis peritonei, an unusual abdominal carcinomatosis: report of two cases].
  • [Transliterated title] La gliomatose péritonéale: un aspect inhabituel de carcinomatose: à propos de deux cas.
  • We report on 2 cases of ovarian teratoma associated with gliomatosis peritonei in 2 young girls aged 9 and 14 years.
  • Gliomatosis peritonei is an unusual miliary-like peritoneal carcinomatosis of glial tissue.
  • In our experience, follow-up was important to detect abdominal recurrence of glial implants, which had to be removed by iterative surgery.
  • [MeSH-minor] Abdomen / pathology. Adolescent. Child. Female. Humans. Neoplasm Metastasis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20452193.001).
  • [ISSN] 1769-664X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Sheen-Chen SM, Liu YW, Sun CK, Lin SE, Eng HL, Huang WT, Ko SF: Abdominal carcinomatosis attributed to metastatic breast carcinoma. Dig Dis Sci; 2008 Nov;53(11):3043-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal carcinomatosis attributed to metastatic breast carcinoma.
  • A 41-year-old female suffered from epigastralgia and intermittent constipation for 10 months, and abdominal fullness and intermittent pain for 6 months, before seeking help.
  • Double contrast barium study of the colon showed multiple indentations on the sigmoid, ascending, and proximal transverse portions with tethered adjacent mucosal outline as well as the presence of ascites compatible with peritoneal carcinomatosis.
  • Due to the persistent abdominal complaints, laparotomy was done.
  • On opening abdominal cavity, massive yellowish ascites was noted.
  • Histologic findings and results of immunohistochemical stains were consistent with diagnosis of primary breast cancer with metastasis to ovary and omentum.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal / secondary. Omentum. Ovarian Neoplasms / secondary. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1960 May;15:573-8 [13839915.001]
  • [Cites] J Clin Gastroenterol. 1988 Apr;10(2):213-7 [2843590.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):397-401 [12893207.001]
  • [Cites] Obstet Gynecol. 1994 Sep;84(3):449-52 [8058246.001]
  • [Cites] Am J Dig Dis. 1972 Oct;17 (10 ):881-6 [5073677.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):102-5 [10094888.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1482-9 [16224215.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):124-8 [7557597.001]
  • [Cites] Eur J Gynaecol Oncol. 1992;13(1 Suppl):85-8 [1324842.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):937-40 [11485532.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):41-4 [9234919.001]
  • [Cites] World J Surg. 2003 Jan;27(1):10-3 [12557031.001]
  • [Cites] Obstet Gynecol. 1975 Apr;45(4):391-6 [1121370.001]
  • (PMID = 18807183.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Gómez Portilla A, Cendoya I, Olabarria I, Echevarría J, Martínez de Lecea C, Romero E, Guede N, Moraza N, Fernández E, Kvadatze M, Larrabide I, Valdovinos M, Ruiz de Alegría N, Fernández JL, Castillo C: [Open vacuum-pack abdomen. An ideal technique for deferred temporary abdominal closure in complications after cytoreduction surgery and intraperitoneal chemotherapy with hyperthermia due to peritoneal cancer]. Cir Esp; 2008 Oct;84(4):215-20
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Open vacuum-pack abdomen. An ideal technique for deferred temporary abdominal closure in complications after cytoreduction surgery and intraperitoneal chemotherapy with hyperthermia due to peritoneal cancer].
  • [Transliterated title] Open vacuum-pack, técnica ideal del cierre abdominal temporal diferido en las complicaciones tras cirugía citorreductora y quimioterapia intraperitoneal con hipertermia por carcinomatosis peritoneal.
  • INTRODUCTION: The use of a new therapeutic alternative involving cytoreductive surgery with perioperative intraperitoneal chemotherapy in the treatment of patients suffering from peritoneal carcinomatosis represents a new challenge for the multidisciplinary teams caring for these patients.
  • In this presentation we explain the special characteristics of these patients compared to the usual surgical patients, the possible physiopathological mechanisms which may give rise to the different types of complications, the circumstances when a temporary abdominal closure is necessary, the ideal conditions required for an optimal technique, and finally our experience with the open vacuum abdomen technique in the treatment of the complications that appear in patients treated by this new triple combined therapy.
  • PATIENTS AND METHODS: Based on our personal experience in the treatment of 110 cytoreductions carried out between February 1997 and February 2007 on 71 patients suffering from peritoneal carcinomatosis of various origins.
  • The abdominal situation made a temporary closure desirable in 17 patients, having applied an open vacuum abdomen technique on every occasion.
  • RESULTS: A total of 52 open vacuum abdomen procedures were required (median, 2.8 per patient; range, 1-10) before the abdominal complication could be completely kept under control in these 17 patients.
  • Only 2 postoperative intestinal fistulas were directly related to this technique, and a primary closure of the whole abdominal wall was possible in 11 of these patients (66%).
  • CONCLUSIONS: As a consequence of this experience, in our opinion, the open vacuum abdomen is the ideal election technique to be employed in any temporary closure of the abdominal cavity for whatever reason it is required, including the worst possible surgical scenario, as we have demonstrated in the treatment of surgical complications after cytoreductive procedures and intraperitoneal chemohyperthermia.
  • [MeSH-major] Abdomen / surgery. Antineoplastic Agents / administration & dosage. Carcinoma / drug therapy. Carcinoma / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Peritoneum / surgery. Postoperative Complications
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Hyperthermia, Induced. Male. Negative-Pressure Wound Therapy. Neoplasm Staging. Perioperative Care. Reoperation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18928772.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Olivier RI, van Beurden M: Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations". Gynecol Oncol; 2005 Nov;99(2):520-1
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
  • [MeSH-major] Abdominal Neoplasms / genetics. Breast Neoplasms / genetics. Carcinoma / genetics. Genes, BRCA1. Genes, BRCA2. Germ-Line Mutation. Ovarian Neoplasms / prevention & control


10. Garg R, Zahurak ML, Trimble EL, Armstrong DK, Bristow RE: Abdominal carcinomatosis in women with a history of breast cancer. Gynecol Oncol; 2005 Oct;99(1):65-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal carcinomatosis in women with a history of breast cancer.
  • (1) characterize the etiology of abdominal carcinomatosis, (2) identify clinical features predictive of primary ovarian/peritoneal cancer, and (3) evaluate the survival impact of cytoreductive surgery among patients with advanced ovarian/peritoneal cancer and a history of breast cancer.
  • METHODS: Patients with a history of prior breast cancer undergoing surgical exploration for abdominal carcinomatosis between 1/1/88 and 12/31/02 were retrospectively identified from tumor registry databases.
  • Logistic regression analysis was used to explore clinical characteristics predictive of primary ovarian/peritoneal cancer versus recurrent breast cancer.
  • RESULTS: Seventy-nine patients underwent surgery for abdominal carcinomatosis a median of 5.39 years after initial breast cancer diagnosis.
  • Abdominal carcinomatosis was due to primary ovarian/primary peritoneal cancer in 74.7% of cases.
  • A history of Stage I breast cancer [OR = 10.73, 95%CI = 2.6-43.7, P < 0.001] and the lack of a prior breast cancer recurrence [OR = 10.60, 95%CI = 2.5-45.2, P < 0.001] were independently predictive of primary ovarian/peritoneal cancer.
  • Among patients with primary ovarian/peritoneal cancer, optimal (< or =1 cm) cytoreductive surgery was associated with a median survival of 44.0 months compared to 18.0 months for patients with suboptimal residual disease [HR = 6.81, 95%CI = 3.37-13.77, P < 0.0001].
  • CONCLUSIONS: Among patients with prior breast cancer presenting with abdominal carcinomatosis, early-stage disease and the absence of a prior recurrence were predictive of primary ovarian/peritoneal cancer.
  • Optimal cytoreductive surgery was associated with a significant survival advantage for patients with primary ovarian/peritoneal cancer.
  • [MeSH-major] Abdominal Neoplasms / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery. Proportional Hazards Models. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15979132.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. de Brito Galvao JF, Pressler BM, Freeman LJ, Rohleder JJ, Burgess RC, Ramos-Vara JA: Mucinous gastric carcinoma with abdominal carcinomatosis and hypergastrinemia in a dog. J Am Anim Hosp Assoc; 2009 Jul-Aug;45(4):197-202
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous gastric carcinoma with abdominal carcinomatosis and hypergastrinemia in a dog.
  • Abdominal radiographs and ultrasound revealed significant gastric wall thickening and a peripancreatic mass, and serum gastrin concentration was increased (127 pg/mL, reference range 10 to 40 pg/mL).
  • Mucinous gastric carcinoma with carcinomatosis was diagnosed by histopathological examination of surgically excised tissues.
  • [MeSH-major] Abdominal Neoplasms / veterinary. Adenocarcinoma, Mucinous / veterinary. Dog Diseases / diagnosis. Gastrins / blood. Pancreatic Neoplasms / veterinary. Stomach Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19570904.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gastrins
  •  go-up   go-down


12. Neumann G, Rasmussen KL, Petersen LK: Cervical adenosquamous carcinoma: tumor implantation in an episiotomy scar. Obstet Gynecol; 2007 Aug;110(2 Pt 2):467-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A 35-year-old woman with cervical adenosquamous carcinoma diagnosed during delivery was treated with radical abdominal hysterectomy with bilateral pelvic lymphadenectomy.
  • Relapse occurred rapidly, and surgical exenteration was initiated but abandoned intraoperatively due to the presence of intra-abdominal carcinomatosis.
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Female. Humans. Hysterectomy. Lymph Node Excision. Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local. Pregnancy. Puerperal Disorders / diagnosis. Puerperal Disorders / pathology. Puerperal Disorders / therapy


13. Lin CY, Huang JS, Jwo SC, Chen HY: Recurrent gastric adenocarcinoma presenting as acute appendicitis: a case report. Int J Clin Pract Suppl; 2005 Apr;(147):89-91
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of acute appendicitis due to recurrent metastatic gastric adenocarcinoma involving only appendix, without the evidence of abdominal carcinomatosis 2 years after initial diagnosis of the primary gastric lesion.
  • [MeSH-major] Adenocarcinoma / secondary. Appendiceal Neoplasms / secondary. Appendicitis / etiology. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Appendicitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15875636.001).
  • [ISSN] 1368-504X
  • [Journal-full-title] International journal of clinical practice. Supplement
  • [ISO-abbreviation] Int J Clin Pract Suppl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Lacueva J, Gallego J, Díaz-González JA: Updating controversies on the multidisciplinary management of gastric cancer. Clin Transl Oncol; 2010 Oct;12(10):677-85
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Local relapses in the tumour bed and regional lymph nodes, peritoneal spread as abdominal carcinomatosis, and distant metastasis are common mechanisms of failure after a R0 resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2010 May 10;28(14):2430-6 [20368551.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Ann Oncol. 2010 Jan;21(1):67-70 [19605503.001]
  • [Cites] Radiother Oncol. 2009 Aug;92(2):164-75 [19375186.001]
  • [Cites] Surg Oncol. 2009 Dec;18(4):322-33 [18922689.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14 (7):2012-8 [18381939.001]
  • [Cites] Surg Endosc. 2009 Feb;23(2):231-41 [18813972.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):929-34 [9869212.001]
  • [Cites] Ann Oncol. 2008 Aug;19(8):1450-7 [18558665.001]
  • [Cites] Radiother Oncol. 2009 Aug;92(2):176-83 [19586672.001]
  • [Cites] Arch Surg. 2004 Jan;139(1):20-6 [14718269.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3647-50 [14512396.001]
  • [Cites] J Thorac Cardiovasc Surg. 2009 Sep;138(3):594-602; discussion 601-2 [19698841.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):661-5 [16621433.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):655-60 [16618532.001]
  • [Cites] Surgery. 2002 Apr;131(4):401-7 [11935130.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):139-46; discussion 146 [15895452.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1522-30 [10188901.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] J Gastrointest Surg. 2004 May-Jun;8(4):454-63 [15120371.001]
  • [Cites] Ann Surg Oncol. 2010 Sep;17(9):2370-7 [20336386.001]
  • [Cites] World J Gastroenterol. 2009 Nov 14;15(42):5352-9 [19908346.001]
  • [Cites] Am J Surg. 2003 Jul;186(1):23-7 [12842743.001]
  • [Cites] Surg Oncol. 1994 Feb;3(1):37-44 [8186869.001]
  • [Cites] J Surg Oncol. 2008 Sep 15;98(4):273-6 [18726891.001]
  • [Cites] BMJ. 2004 Jun 19;328(7454):1490 [15205295.001]
  • [Cites] Ann Surg. 2007 Jan;245(1):68-72 [17197967.001]
  • [Cites] Cancer Treat Rev. 2007 Dec;33(8):729-40 [17935888.001]
  • [Cites] J Surg Oncol. 2007 May 1;95(6):461-8 [17192913.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1237-44 [15718321.001]
  • [Cites] World J Surg. 2001 Aug;25(8):985-90 [11571980.001]
  • [Cites] Lancet Oncol. 2009 Sep;10 (9):903-12 [19717092.001]
  • [Cites] Ann Surg Oncol. 2004 Jun;11(6):629-35 [15150070.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1103-9 [16106493.001]
  • [Cites] Semin Surg Oncol. 1999 Sep;17(2):103-7 [10449681.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2774-80 [15254045.001]
  • [Cites] Surg Endosc. 2008 Aug;22(8):1781-9 [18437472.001]
  • [Cites] Ann Oncol. 2009 May;20 Suppl 4:34-6 [19454457.001]
  • [Cites] J Surg Oncol. 2009 Sep 15;100(4):311-6 [19697437.001]
  • [Cites] Hepatogastroenterology. 2006 May-Jun;53(69):473-8 [16795995.001]
  • [Cites] World J Gastroenterol. 2004 Sep 15;10(18):2727-30 [15309728.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Ann Surg Oncol. 2009 Dec;16(12):3227-36 [19777180.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):965-74 [12788435.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S97-100 [16399443.001]
  • [Cites] J Am Coll Surg. 2009 Feb;208(2):173-8 [19228527.001]
  • [Cites] J Surg Oncol. 2002 Jun;80(2):72-8 [12173383.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):851-6 [19139439.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3953-8 [16921048.001]
  • [Cites] Br J Surg. 2005 Mar;92(3):370-5 [15739249.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):74-81 [16371739.001]
  • [Cites] Br J Surg. 1996 May;83(5):672-4 [8689216.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):232-7 [15650632.001]
  • [Cites] JAMA. 2010 May 5;303(17):1729-37 [20442389.001]
  • [Cites] Ann Surg. 2009 Aug;250(2):242-6 [19638909.001]
  • [Cites] Scand J Surg. 2006;95(4):260-9 [17249275.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Lancet. 2010 Aug 28;376(9742):687-97 [20728210.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):992-1000; discussion 1000-1 [18043101.001]
  • [Cites] Semin Radiat Oncol. 2002 Apr;12(2):187-95 [11979420.001]
  • [Cites] Ann Surg Oncol. 2010 Dec;17(12):3173-80 [20585870.001]
  • [Cites] Ann Surg Oncol. 2010 Oct;17(10):2733-9 [20490698.001]
  • [Cites] Ann Surg Oncol. 2009 Oct;16(10):2738-43 [19636636.001]
  • [Cites] World J Gastroenterol. 2006 Dec 21;12(47):7676-83 [17171799.001]
  • (PMID = 20947482.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Markman M, Belinson J: A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers. J Cancer Res Clin Oncol; 2005 Jan;131(1):26-30
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers.
  • PURPOSE: Optimal management of patients with advanced ovarian or primary peritoneal cancers who have received, and achieved an excellent response to, neoadjuvant chemotherapy remains undefined.
  • METHODS: Five patients are briefly presented who were found to have extensive intra-abdominal carcinomatosis from ovarian/peritoneal cancers and were initially treated with a carboplatin/paclitaxel-based neoadjuvant chemotherapy program.
  • RESULTS AND CONCLUSION: In the absence of definitive data from randomized phase-3 trials defining optimal management in this setting, a rational argument can be provided supporting the use of this multi-modality management strategy (neoadjuvant chemotherapy followed by surgery and regional chemotherapy) in carefully selected patients presenting with extensive ovarian or primary peritoneal cancers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Nov 15;92(10):2585-91 [11745193.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):694-8 [11821450.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1479-84 [1517791.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):106-15 [10623700.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):431-6 [9887245.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):57-60 [3277734.001]
  • [Cites] Gynecol Oncol. 1998 May;69(2):103-8 [9600815.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2329-34 [11413522.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(6):389-94 [2311166.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3380-4 [2720692.001]
  • [Cites] Cancer Treat Rep. 1983 Dec;67(12):1085-92 [6228294.001]
  • [Cites] Gynecol Oncol. 2003 Jan;88(1):9-16 [12504620.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):269-74 [10985879.001]
  • [Cites] Lancet Oncol. 2003 May;4(5):277-83 [12732164.001]
  • [Cites] Cancer Chemother Pharmacol. 1986;18(3):235-8 [3542268.001]
  • [Cites] N Engl J Med. 1995 Mar 9;332(10):629-34 [7845426.001]
  • [Cites] Cancer Treat Rep. 1983 Mar;67(3):235-8 [6682012.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] Int J Gynecol Cancer. 2001 Nov-Dec;11(6):466-70 [11906550.001]
  • [Cites] Gynecol Oncol. 1999 Jan;72(1):93-9 [9889037.001]
  • [Cites] Gynecol Oncol. 2002 May;85(2):351-5 [11972399.001]
  • [Cites] Gynecol Oncol. 1998 Apr;69(1):17-22 [9570993.001]
  • [Cites] Ann Intern Med. 1982 Dec;97(6):845-51 [6890785.001]
  • [Cites] AJR Am J Roentgenol. 1995 Oct;165(4):875-8 [7676985.001]
  • [Cites] J Clin Oncol. 1991 Oct;9(10):1801-5 [1919630.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):159-66 [1468693.001]
  • (PMID = 15449183.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Bereder J, Glehen O, Habre J, Desantis M, Cotte E, Mounier N, Ray-Cocquard I, Karimdjee B, Bakrin N, Bernard J, Benchimol D, Gilly F: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from ovarian cancer: A multiinstitutional study of 246 patients. J Clin Oncol; 2009 May 20;27(15_suppl):5542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from ovarian cancer: A multiinstitutional study of 246 patients.
  • For peritoneal carcinomatosis new treatment combining cytoreductive surgery with heated intraperitoneal per operative chemotherapy (HIPEC) may improve survival.
  • METHODS: Retrospective bicentric study of 246 patients with peritoneal carcinomatosis from ovarian cancer were performed to evaluate HIPEC and to identify prognostic factors.
  • Peritoneal Cancer Index (PCI) assess tumor load and completeness cytoreductive score (CCS) was used to give quality of resection CC0 (no visible tumor), CC1 (persistent diffuse lesions < 2.5mm), CC2 (2.5mm < CC2 < 25mm) and over CC3 status.
  • Independent prognostic factors for survival were the carcinomatosis extent, the completeness of cytoreductive surgery (HR = 2.26 IC95 [1.3-3.91]), performance status (HR = 4.3 IC95 [1.23-14.4]) and redo procedure (HR = 0.9 IC95 [0.001-0.9]).
  • To date in selected patients, HIPEC allows to reach the longest median time survival in recurrent peritoneal carcinomatosis from ovarian cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962514.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kamikozuru H, Hayashi K, Kuramochi H, Nakajima G, Yamamoto M: Pharmacokinetics of intraperitoneal docetaxel and S-1 in patients with gastric cancer with peritoneal carcinomatosis. J Clin Oncol; 2009 May 20;27(15_suppl):e15626

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of intraperitoneal docetaxel and S-1 in patients with gastric cancer with peritoneal carcinomatosis.
  • : e15626 Background: One of the most causes of death from gastric cancer is peritoneal cartinomatosis.
  • Intraperitoneal docetaxel infusion is expected to be a new strategy for a treatment of peritoneal carcinomatosis.
  • The purpose of this study is to evaluate the plasma and peritoneal pharmacokinetic of intraperitoneal docetaxel infusion in combination with oral administration of S-1.
  • METHODS: Eight patients with peritoneal carcinomatosis of advanced gastric cancer were enrolled.
  • Blood and peritoneal fluid were collected before administration, on completion of the docetaxel infusion(hour 0) and at hours 1,2,4,6,12,24,48,and 72 after completion of the infusion of the docetaxel.
  • Plasma and peritoneal fluid concentrations of docetaxel and 5FU were evaluated.
  • RESULTS: The mean peak peritoneal and plasma concentrations of docetaxel were 18.6×10<sup>3</sup> ng/ml (at hour 0) and 45 ng/ml (at hour 0 to 2), respectively.
  • The peritoneal concentrations of docetaxel were remained even after 24 and 72 hours (24 hours: 1150ng/ml, 72 hours: 74ng/ml).
  • The mean peritoneal and plasma areas under the curves (AUC) of docetaxel were 141×10<sup>3</sup> ng/ml×hr and 480 ng/ml×hr, respectively.
  • The mean peritoneal concentrations of 5FU kept over 60% of plasma concentrations (plasma: 164.3ng/ml, peritoneal: 105ng/ml).
  • 5FU concentrations were well transfered in peritoneal fluid from plasma via oral S-1 administration.
  • Intraperitoneal docetaxel in combination with S-1 orally may be a useful regimen to the patients with carcinomatosis of advanced gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962699.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Hompes D, D'Hoore A, Van Cutsem E, Ceelen W, Peeters M, Van der Speeten K, Bertrand C, Kerger J, Legendre H: Evaluation of the treatment of peritoneal carcinomatosis of colorectal cancer (CRC) with complete cytoreduction and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: A Belgian multicenter prospective phase II clinical study. J Clin Oncol; 2009 May 20;27(15_suppl):4101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the treatment of peritoneal carcinomatosis of colorectal cancer (CRC) with complete cytoreduction and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: A Belgian multicenter prospective phase II clinical study.
  • : 4101 Background: Up to 25% of patients with metastatic CRC present with peritoneal carcinomatosis (PC) as the only site of metastases.
  • Median PCI (peritoneal cancer index) was 11 [1-22], with a median of 6 [1-11] abdominal regions involved and a median lesion size score of 3 [1-3].
  • Complication rate was 52.1%, with 18 intra- and 17 extra-abdominal complications.
  • Occurrence of intra-abdominal complications significantly affected hospital stay (p=0.0012), but no risk factors for occurrence of postoperative complications could be clearly identified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Hayashi K, Kamikozuru H: Pharmacokinetics of intraperitoneal docetaxel and S-1 in patients with gastric cancer with peritoneal carcinomatosis. J Clin Oncol; 2009 May 20;27(15_suppl):e15672

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of intraperitoneal docetaxel and S-1 in patients with gastric cancer with peritoneal carcinomatosis.
  • : e15672 Background: One of the most causes of death from gastric cancer is peritoneal cartinomatosis.
  • Intraperitoneal docetaxel infusion is expected to be a new strategy for a treatment of peritoneal carcinomatosis.
  • The purpose of this study is to evaluate the plasma and peritoneal pharmacokinetic of intraperitoneal docetaxel infusion in combination with oral administration of S-1.
  • METHODS: Eight patients with peritoneal carcinomatosis of advanced gastric cancer were enrolled.
  • Blood and peritoneal fluid were collected before administration, on completion of the docetaxel infusion(hour 0) and at hours 1,2,4,6,12,24,48,and 72 after completion of the infusion of the docetaxel.
  • Plasma and peritoneal fluid concentrations of docetaxel and 5FU were evaluated.
  • RESULTS: The mean peak peritoneal and plasma concentrations of docetaxel were 18.6×103 ng/ml (at hour 0) and 45 ng/ml (at hour 0 to 2), respectively.
  • The peritoneal concentrations of docetaxel were remained even after 24 and 72 hours (24 hours: 1150ng/ml, 72 hours: 74ng/ml).
  • The mean peritoneal and plasma areas under the curves (AUC) of doceta×el were 141x103 ng/ml×hr and 480 ng/ml×hr, respectively.
  • The mean peritoneal concentrations of 5FU kept over 60% of plasma concentrations (plasma: 164.3ng/ml, peritoneal: 105ng/ml).
  • 5FU concentrations were well transfered in peritoneal fluid from plasma via oral S-1 administration.
  • Intraperitoneal docetaxel in combination with S-1 orally may be a useful regimen to the patients with carcinomatosis of advanced gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962844.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Murata S, Naito H, Yamamoto H, Mekata E, Shimizu T, Shiomi H, Naka S, Abe H, Kurumi Y, Tani T: Phase II trial of adjuvant hyperthermic intraperitoneal chemotherapy with three drugs for the prophylactic treatment of carcinomatosis after resection of advanced gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15588

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of adjuvant hyperthermic intraperitoneal chemotherapy with three drugs for the prophylactic treatment of carcinomatosis after resection of advanced gastric cancer.
  • Three patients with pT3 had recurrence of pleural dissemination (n=1), lymph node metastases (n=1), or pulmonary metastases and peritoneal dissemination (n=1).
  • A total of 7 patients had postoperative complications such as continuous pancreatic juice secretion (13.8%), abdominal abscess (10.3%), leakage of the anastomosis (3.4%), and pulmonary insufficiency (10.3%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962346.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Chua TC, Robertson G, Farrell R, Liauw W, Yan TD, Morris DL: Systematic review of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for ovarian peritoneal carcinomatosis: A more efficacious way of delivering intraperitoneal chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):5524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic review of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for ovarian peritoneal carcinomatosis: A more efficacious way of delivering intraperitoneal chemotherapy.
  • : 5524 Background: Advanced and recurrent ovarian cancer results in extensive dissemination of tumor within the peritoneal cavity.
  • The current evidence suggests that cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) may be a feasible option with potential benefits compared to the current standard of care in the treatment of peritoneal carcinomatosis from ovarian cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962480.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Glehen O, Elias D, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Association Française de Chirurgie: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from digestive or primitive origin: A multi-institutional study of 1,290 patients. J Clin Oncol; 2009 May 20;27(15_suppl):4102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from digestive or primitive origin: A multi-institutional study of 1,290 patients.
  • : 4102 Background: Peritoneal carcinomatosis (PC) from non-gynecologic malignancies has long been regarded a terminal disease with a short median survival.
  • The principal etiologies of PC were colorectal adenocarcinoma (N=523), pseudomyxoma peritonei (N=301), gastric adenocarcinoma (N=159), peritoneal mesothelioma (N=88), and appendiceal adenocarcinoma (N=50).
  • The overall median survival was 34 months: 30 months for colorectal PC, not reached for pseudomyxoma peritonei, 9 months for gastric PC, 41 months for peritoneal mesothelioma, and 77 months for PC from appendiceal adenocarcinoma.
  • Independent prognostic indicators by multivariate analysis were the institution's experience, etiology, completeness of cytoreductive surgery, extent of carcinomatosis, and lymph node involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961196.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Ströhlein M, Lordick F, Rüttinger D, Schemanski O, Jaeger M, Lindhofer H, Hennig M, Lahr A, Heiss M: Peritoneal carcinomatosis immunotherapy with the trifunctional anti-EpCAM x anti-CD3 antibody catumaxomab in patients with colon, gastric, or pancreatic cancer: Long-term results after a 2-year follow-up. J Clin Oncol; 2009 May 20;27(15_suppl):3033

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal carcinomatosis immunotherapy with the trifunctional anti-EpCAM x anti-CD3 antibody catumaxomab in patients with colon, gastric, or pancreatic cancer: Long-term results after a 2-year follow-up.
  • : 3033 Background: Peritoneal carcinomatosis (PC) from gastrointestinal (GI) cancer is associated with a poor outcome.
  • The most common drug-related adverse events at the MTD were fever, vomiting, abdominal pain, skin toxicity, and nausea.
  • EpCAM-positive cells in peritoneal lavage samples decreased in six of 10 evaluable patients.
  • Median survival from the time of diagnosis of PC was 502 days in study patients versus 180 days in control patients (log-rank p = .0083).
  • Elimination of tumor cells from peritoneal lavage samples, delayed disease progression, and prolonged survival indicate that intraperitoneal catumaxomab is a promising option for the treatment of PC from GI cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962081.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Gallego R, Fuster D, Ginés A, Ortín J, Ayuso JR, Momblan D, Arguis P, Conill C, Pons F, Maurel J: Usefulness of PET/CT in the diagnosis of distant metastases of potentially operable gastric adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15598

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of PET/CT in the diagnosis of distant metastases of potentially operable gastric adenocarcinoma.
  • 1) To evaluate the usefulness of Positron Emission Tomography with combined 18F-Fluorodeoxyglucose with Computed Tomography (PET/CT) in the diagnosis of distant metastases in patients with gastric adenocarcinoma (GAC) compared to spiral double contrast thoracoabdominal Computed Tomography (CT);.
  • 2) To establish the utility of PET/CT in the detection of peritoneal carcinomatosis compared to laparoscopy.
  • RESULTS: Distant metastases were found in 9/30 cases: carcinomatosis (3), retroperitoneal (3) or mediastinal (2) pathological lymph nodes and one case of bone metastases (1).
  • In 1/3 patients with histopathological confirmed diagnosis of peritoneal carcinomatosis by laparoscopic findings was negative by PET/CT, and considered as a false negative case.
  • On the other hand, 3 patients with initially positive peritoneal carcinomatosis by invasive laparoscopy were finally diagnosed as benign lesions.
  • 1) PET/CT is useful in the diagnosis of distant metastases in patients with GAC 2) Further studies are needed to establish the role of PET/CT to detect peritoneal carcinomatosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962880.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Bereder I, Guerin O, Boulahssass R, Couderc A, Mailland V, Macone F, Mounier N, Habre J, Karimdjee-Soilihi B, Bereder J: Cytoreductive surgery combined with peritoneal intraoperative heated chemotherapy for management of peritoneal carcinomatosis in 59 adults older than age 65. J Clin Oncol; 2009 May 20;27(15_suppl):e20657

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery combined with peritoneal intraoperative heated chemotherapy for management of peritoneal carcinomatosis in 59 adults older than age 65.
  • : e20657 Background: Peritoneal carcinomatosis (PC) has long been regarded as a terminal disease with short median survival.
  • The principal etiologies of PC in group1 were recurrent ovarian cancer (N=33), colorectal cancer (N=9), peritoneal mesothelioma (N=6), pseudomyxoma (N=9) and sarcomatosis (N=2).
  • Independent prognostic factors for survival by multivariate analysis were extent of carcinomatosis, completeness of cytoreductive surgery and performance status.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961621.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ardalan B, Feagans M, Mezentsev D, Jones C, Subbarayan PR, Walker G, Sapp M, Stephenson K, Ness J, Franceschi D, Livingstone A: Phase II study of bevacizumab (B), camptosar (I), high-dose 24-hour continuous intravenous infusion of floxuridine (F) and leucovorin (L) in patients with previously untreated metastatic colon cancer. (B-IFL). J Clin Oncol; 2009 May 20;27(15_suppl):e15114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 8 pt (36%) had bilobar liver disease and involvement of 1 other organ, 6 pt (27%) had bilobar liver disease with involvement of ≥ 2 other organs; 5 pt (23.5%) had bilobar liver disease; 2 pt (9%) had abdominal carcinomatosis; 1 pt (4.5 %) had involvement in one liver lobe.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960848.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Alexandre J, Ray-Coquard I, Selle F, Floquet A, Cottu P, Weber B, Falandry C, Lebrun D, Pujade-Lauraine E, GINECO-Group: Clinical presentation and sensitivity to platinum-based chemotherapy (CT) of mucinous advanced epithelial ovarian carcinoma (M-AEOC): The GINECO-Group experience. J Clin Oncol; 2009 May 20;27(15_suppl):5572

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peritoneal metastasis (mets) appeared more limited in M- than in S-AEOC pts since stages IIB-IIIB were more frequent (31% versus 19%, p = 0.001) and complete resection more frequently obtained (45% of stage II-III pts versus 29%, p = 0.06) in M-AEOC.
  • Extra-peritoneal mets (stage IV) were more frequent in M- than in S-AEOC pts (30% versus 15%, p = 0.004), specially liver mets (44% of stage IV pts versus 23%, p = 0.06).
  • CONCLUSIONS: Compared to S-AEOC, M-AEOC is characterized by more limited peritoneal carcinomatosis but more frequent liver mets.
  • M-AEOC appears to be a highly chemoresistant disease and complete resection of peritoneal mets is unable to reverse its adverse prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962610.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Beyer I, Bauerschmitz GJ, Breidenbach M, Dragoi A, Niederacher D, Janni W, Rein DT: Gene therapy for pretreated ovarian cancer via a novel fiber modified mdr1 targeting conditionally replicating adenovirus. J Clin Oncol; 2009 May 20;27(15_suppl):e16513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A mouse model of peritoneal carcinomatosis was used to evaluate the efficacy of a combined chemo- and gene therapy for OC.
  • Moreover, in a therapeutic orthotopic mouse model of peritoneal carcinomatosis, dramatically enhanced survival was noted with Ad5/3MDR1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960759.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Veroni S, Terzopoulou K, Anagnostopoulou I, Vassilakaki T, Grammatoglou X, Rammou R: Extraovarian peritoneal serous papillary carcinoma: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):879-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraovarian peritoneal serous papillary carcinoma: a case report.
  • BACKGROUND: Extraovarian peritoneal serous papillary carcinoma (EPSPC) is a rare cancer closely related to ovarian carcinoma and characterized by abdominal carcinomatosis without an identifiable abdominal primary tumor.
  • Peritoneal carcinomatosis without involvement of the ovaries was found.
  • The histologic and immunohistochemical study of peritoneal biopsy specimens resulted in the diagnosis of EPSPC.
  • CONCLUSION: The combination of cytology, histology, immunohistochemistry and clinical data is a reliable method for the preoperative diagnosis of EPSPC, allowing prompt chemotherapy as surgery may not be indicated in most cases.
  • [MeSH-major] Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Ovary / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Proteins / metabolism. Vacuoles / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053561.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


30. Seo H, Sung H, Choi I, Oh S, Seo J, Shin S, Kim Y, Park K, Kim J: Prognostic significance of serum vascular endothelial growth factor per platelet count in gastric cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e22031

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the multivarivate analysis, performance status (P=0.025), the presence of peritoneal carcinomatosis (P=0.006), serum VEGF per platelet (P=0.005) were found to be significantly associated with poor progression free survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963147.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Qu QL, Zhang YG, Yang LZ, Sun L: [Intraperitoneal chemotherapy with mitomycin C bound to activated carbon nanoparticles for nude mice bearing human gastric carcinoma]. Zhonghua Zhong Liu Za Zhi; 2006 Apr;28(4):257-60
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An experiment on nude mice model with transplanted human gastric cancer in 6 groups was completed to assess the effects of drugs on intra-abdominal carcinomatosis.
  • MMC-ACNP was superior to MMC aqueous solution in controlling carcinomatosis and tumor growth by intraperitoneal administration.
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Animals. Drug Carriers. Drug Delivery Systems. Female. Humans. Injections, Intraperitoneal. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Nanoparticles. Neoplasm Transplantation. Thrombocytopenia / chemically induced

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. ACTIVATED CHARCOAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875622.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Drug Carriers; 16291-96-6 / Charcoal; 50SG953SK6 / Mitomycin
  •  go-up   go-down


32. Wu WC, Lai CI, Huang LC, Chiu TH, Hung YC, Chang WC: Normal-sized ovarian papillary serous carcinoma: a case report. Eur J Gynaecol Oncol; 2010;31(5):567-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a 46-year-old woman with progressive abdominal fullness of one week's duration.
  • The medical evaluation revealed abdominal carcinomatosis with normal-sized ovaries and an elevated serum CA-125 level of 147,365.8 U/ml.
  • Cytoreductive surgery (hysterectomy, bilateral salpingo-oophorectomy, omentectomy, lymphadenectomy, infracolic omentectomy, peritoneal biopsy, washing cytology, and appendectomy) was performed.
  • Normal-sized ovarian serous surface papillary carcinomas should be kept in mind as an origin of disease in patients who have peritoneal carcinomatosis, which sometimes is a diagnostic dilemma of the disease source.
  • We report this case to emphasize the clinical symptoms and importance of the early and accurate diagnosis of a normal-sized ovarian papillary serous carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21061803.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


33. Ferrandina G, Legge F, Salutari V, Paglia A, Testa A, Scambia G: Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. Eur J Cancer; 2006 Sep;42(14):2296-302
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In stage III-IV cases (n = 270), diffuse abdominal carcinomatosis occurred in 62.1% of cases, while recurrences presented as a single lesion or multiple nodules occurred in 9.9% and 26.7% of cases, respectively.
  • Pattern of recurrence as carcinomatosis was shown to be associated with unfavourable outcome even when stratified according to platinum free interval (PFI) duration.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901687.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. Sawamura A: [Surgical intervention in palliative care]. Nihon Rinsho; 2007 Jan;65(1):89-92
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In palliative care, surgical intervention is contra-indicated if there is intra-abdominal carcinomatosis as evidenced by diffuse intra-abdominal tumors, and massive ascites which re -accumulates rapidly after paracentesis.

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233421.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 7
  •  go-up   go-down


35. Zhao DB, Shan Y, Wang CF, Wu JX, Shao YF, Zhao P: [Surgical treatment for colorectal cancer with simultaneous hepatic metastasis]. Zhonghua Zhong Liu Za Zhi; 2007 Jul;29(7):552-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multivariate analysis showed that liver metastasis resection, abdominal carcinomatosis, chemotherapy and intervention treatment were the most important prognostic factors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Colectomy / methods. Female. Follow-Up Studies. Hepatectomy / methods. Humans. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Rectum / surgery. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069642.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


36. Ripamonti CI, Easson AM, Gerdes H: Management of malignant bowel obstruction. Eur J Cancer; 2008 May;44(8):1105-15
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of malignant bowel obstruction.
  • Malignant bowel obstruction (MBO) is a common and distressing outcome particularly in patients with bowel or gynaecological cancer.
  • Although surgery should be the primary treatment for selected patients with MBO, it should not be undertaken routinely in patients known to have poor prognostic criteria for surgical intervention such as intra-abdominal carcinomatosis, poor performance status and massive ascites.
  • Self-expanding metallic stents are an option in malignant obstruction of the gastric outlet, proximal small bowel and colon.

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18359221.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics; 0 / Antiemetics; 0 / Gastrointestinal Agents
  •  go-up   go-down


37. Constantinou C, Widom K, Desantis J, Obmann M: Hidradenitis suppurativa complicated by squamous cell carcinoma. Am Surg; 2008 Dec;74(12):1177-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first patient developed diffuse abdominal carcinomatosis from SCC in the anogenital region arising from HS.
  • The second patient developed malignant hypercalcemia, an uncommon complication of cutaneous SCC.
  • The current report represents the largest review of the literature of patients with SCC secondary to longstanding HS.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Hidradenitis Suppurativa / complications. Peritoneal Neoplasms / complications. Skin Neoplasms / complications


38. You YT, Changchien CR, Huang JS, Ng KK: Combining systemic chemotherapy with chemoembolization in the treatment of unresectable hepatic metastases from colorectal cancer. Int J Colorectal Dis; 2006 Jan;21(1):33-7
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of the patients (73%) died of hepatic failure, while the second largest group died of abdominal carcinomatosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemoembolization, Therapeutic / methods. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Palliative Care
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2002 Nov;50(5):383-91 [12439596.001]
  • [Cites] Ann Intern Med. 1987 Oct;107(4):459-65 [2957943.001]
  • [Cites] Cancer. 1990 Jun 1;65(11):2446-50 [2140070.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):1935-40 [15274380.001]
  • [Cites] Radiology. 1993 Nov;189(2):417-22 [8210369.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):770-5 [9221850.001]
  • [Cites] Lancet. 1997 Sep 6;350(9079):681-6 [9291901.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2274-9 [8708717.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):808-15 [9053508.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1407-12 [9807986.001]
  • [Cites] Z Gastroenterol. 2002 Dec;40(12 ):957-64 [12564419.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1413-8 [9807987.001]
  • [Cites] Oncology. 2002;62(3):209-15 [12065867.001]
  • [Cites] Cancer. 1997 Oct 1;80(7):1179-87 [9317168.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343 (13):905-14 [11006366.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1706-12 [8082071.001]
  • [Cites] J Clin Oncol. 1988 Mar;6(3):469-75 [3280741.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):14-20 [7677801.001]
  • [Cites] Br J Surg. 1990 Jul;77(7):779-82 [2200559.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1126-31 [8630887.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):1967-72 [1941055.001]
  • [Cites] Cancer. 1989 Feb 15;63(4):742-7 [2521570.001]
  • [Cites] Ann Intern Med. 1984 May;100(5):736-43 [6231876.001]
  • [Cites] Ann Surg. 1984 May;199(5):502-8 [6721600.001]
  • (PMID = 15942741.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


39. Marchal F, Brunaud L, Bazin C, Boccacini H, Henrot P, Troufleau P, Krakowski I, Regent D: Radiofrequency ablation in palliative supportive care: early clinical experience. Oncol Rep; 2006 Feb;15(2):495-9
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The fifth patient had a local recurrence in the site of a previous nephrectomy with a pancreatic tail extension, and surgical resection was contraindicated because of abdominal carcinomatosis.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391875.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


40. Namwongprom S, Núñez RF, Yeung HW, Kim EE, Macapinlac HA: Unusual adrenal metastasis and abdominal carcinomatosis secondary to Hurthle cell carcinoma of the thyroid. Exp Clin Endocrinol Diabetes; 2007 Nov;115(10):694-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual adrenal metastasis and abdominal carcinomatosis secondary to Hurthle cell carcinoma of the thyroid.
  • Hurthle cell carcinoma (HCC) of the thyroid is an uncommon and relatively rare differentiated thyroid neoplasm.
  • To our knowledge, no reported case of adrenal metastases with abdominal carcinomatosis secondary to HCC of the thyroid has been demonstrated by F-18 FDG PET/CT imaging.
  • In this case report, we describe a patient with HCC who had a left adrenal metastasis with abdominal carcinomatosis that was discovered using F-18 FDG PET/CT imaging.
  • [MeSH-major] Abdominal Neoplasms / radiography. Adenoma, Oxyphilic / radiography. Adrenal Gland Neoplasms / radiography. Carcinoma / radiography. Positron-Emission Tomography. Thyroid Neoplasms / radiography
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058606.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


41. Contreras CM, Badgwell BD, Askew RL, Feig BW, Cormier JN: Radiographic and clinical factors associated with improved outcomes in cancer patients with bowel obstruction. J Clin Oncol; 2009 May 20;27(15_suppl):e20564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 194 patients, 25% had a primary diagnosis of colorectal cancer.
  • Computed tomography, plain radiographs, enteral contrast studies, and other modalities were used for diagnosis in 59%, 26%, 12%, and 3% of patients, respectively.
  • Radiographic images demonstrating low grade obstruction, absence of ascites, and the absence of peritoneal carcinomatosis were associated with improved OS.
  • Additional relevant clinical factors affecting OS included serum albumin level; however, no association was observed for age, tumor type, site of obstruction, previous bowel obstruction, or abdominal exploration.
  • Given that factors such as ascites, peritoneal carcinomatosis and low serum albumin result in poor OS, non-invasive procedures should be considered.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961137.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Ozan H, Ozerkan K, Orhan A: Peritoneal tuberculosis mimicking peritoneal carcinomatosis. Eur J Gynaecol Oncol; 2009;30(4):426-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal tuberculosis mimicking peritoneal carcinomatosis.
  • PURPOSE: The data of 11 peritoneal tuberculosis (TB) patients is discussed in an attempt to better understand this disease.
  • Abdominal swelling and pain, appetite loss, nausea/vomiting, and primary infertility were the most common complaints.
  • Six patients had ovarian/primary peritoneal cancer on laparotomy.
  • They underwent peritoneal or omental biopsies; histopathology revealed caseous granulomatous TB lesions.
  • CONCLUSION: Peritoneal TB should be suspected in endemic areas, especially in young patients considered to have peritoneal carcinomatosis.
  • [MeSH-major] Peritoneal Neoplasms / diagnosis. Peritonitis, Tuberculous / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Ovarian Neoplasms / diagnosis. Young Adult

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19761137.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


43. Savelli L, De Iaco P, Ceccaroni M, Ghi T, Ceccarini M, Seracchioli R, Cacciatore B: Transvaginal sonographic features of peritoneal carcinomatosis. Ultrasound Obstet Gynecol; 2005 Oct;26(5):552-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transvaginal sonographic features of peritoneal carcinomatosis.
  • OBJECTIVES: Peritoneal carcinomatosis involves the dissemination of intra-abdominal tumor tissue often associated with gynecological malignancies.
  • METHODS: The data of 60 patients with surgically and histologically proven peritoneal carcinomatosis were analyzed.
  • Transvaginal sonograms performed within 7 days of admission to the operating theater were re-evaluated in order to identify the sonographic features associated with peritoneal carcinomatosis.
  • RESULTS: Carcinomatosis was revealed in 53/60 cases (88%) by the presence of hypoechoic nodules attached to the peritoneum and visible on transvaginal sonography (TVS).
  • CONCLUSIONS: Peritoneal carcinomatosis has typical features on TVS and, in the vast majority of cases, its genital origin can be correctly hypothesized.
  • Power Doppler sonography strengthens the diagnosis by showing vascularity of the peritoneal implants.
  • In a patient with a known pelvic malignancy or whenever peritoneal carcinomatosis is suspected, TVS can give useful information in order to better assess the presence and extension of metastatic nodules within the abdominal cavity.
  • [MeSH-major] Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Seeding. Omentum / ultrasonography. Ovarian Neoplasms / ultrasonography. Stomach Neoplasms / ultrasonography. Ultrasonography, Doppler / methods. Ultrasonography, Doppler, Color / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 ISUOG.
  • (PMID = 16184510.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Garofalo A, Valle M: Laparoscopy in the management of peritoneal carcinomatosis. Cancer J; 2009 May-Jun;15(3):190-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy in the management of peritoneal carcinomatosis.
  • The use of videolaparoscopy in the assessment of peritoneal carcinomatosis extent is now universally accepted.
  • This procedure allows us to define with certainty the origin of the neoplasm, the peritoneal cancer index (PCI), the involvement of the small bowel and its mesentery, the feasibility of surgery and the index of attainable cytoreduction, the evaluation of an eventual multiorgan resection, and finally results in no mortality and very low morbidity.The indications for laparoscopy are as follows: staging of the carcinomatosis already diagnosed with imaging (CT scan and MRI), staging of carcinomatosis of dubious origin (biopsy), restaging after neoadjuvant chemotherapy, restaging during follow-up in the case of dubious imaging, and restaging after adjuvant chemotherapy.Open (Hasson) technique has always been used in the introduction of the first trocar, and the changing position of the surgical bed allows for the evaluation of all the abdominal quadrants, limiting viscerolysis to the essential minimum to avoid iatrogenic lesions.
  • We excluded patients from peritonectomy if the staging laparoscopy showed a significant involvement of the small bowel or mesentery.We used videolaparoscopy to stage 197 cases of peritoneal carcinomatosis and achieved full laparoscopic PCI assessment in 196 of 197 (99.49%) cases, whereas only 4 of 197 (2.03%) cases were understaged before the routine use of laparoscopic ultrasound.
  • It is now possible, in light of acquired experience, to evaluate with precision the indications, the technique, and the limits of the method both in the assessment of the carcinomatosis extent and in its palliation.
  • [MeSH-major] Laparoscopy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Male. Neoplasm Staging / methods. Treatment Outcome. Video Recording

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19556903.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Elias D, Raynard B, Farkhondeh F, Goéré D, Rouquie D, Ciuchendea R, Pocard M, Ducreux M: Peritoneal carcinomatosis of colorectal origin. Gastroenterol Clin Biol; 2006 Oct;30(10):1200-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal carcinomatosis of colorectal origin.
  • PURPOSE: Complete resection of macroscopic colorectal peritoneal carcinomatosis (PC), followed by intraoperative intraperitoneal chemohyperthermia (IPCH) to treat residual microscopic disease achieves cure in some patients.
  • PATIENTS AND METHODS: From June 1998 to December 2003, thirty patients with macroscopic colorectal PC underwent complete resection of PC followed by IPCH with LOHP performed in an open abdominal cavity.
  • RESULTS: Mean peritoneal tumor extension (Sugarbaker's Score) was 14.3 +/- 3.8, median operative duration, 450 min, and median blood loss, 940 mL.
  • Eleven (37%) patients had associated extra-peritoneal lesions which were resected during the same procedure.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / therapy. Colorectal Neoplasms / pathology. Organoplatinum Compounds / therapeutic use. Peritoneal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075479.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


46. Su HT, Tsai CM, Perng RP: Peritoneal carcinomatosis in lung cancer. Respirology; 2008 May;13(3):465-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal carcinomatosis in lung cancer.
  • BACKGROUND AND OBJECTIVE: A survey was carried out of peritoneal carcinomatosis (PC) in lung cancer.
  • METHODS: A retrospective analysis was conducted of all lung cancer patients with malignant ascites diagnosed between 1990 and 2005 at a general hospital in Taiwan.
  • The most frequent abdominal symptom was abdominal distension.
  • Eighty per cent of the patients developed malignant pleural effusions before the diagnosis of PC.
  • The median survival after diagnosis of PC was 15 days.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Lung Neoplasms / pathology. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399874.001).
  • [ISSN] 1440-1843
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


47. Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ynsa MD, Beltramo JL, Drogoul C, Simonet M, Benoit L, Rat P, Chauffert B: High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg; 2006 Jul;244(1):106-12
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis.
  • OBJECTIVE: To investigate the role of increased intra-abdominal pressure (IAP) on the intratumoral accumulation and the antitumor effect of intraperitoneal cisplatin in rats with advanced peritoneal carcinomatosis.
  • SUMMARY BACKGROUND DATA: To investigate if an active convection, driven by a positive IAP, increases cisplatin penetration and antitumor effectiveness in a model of advanced peritoneal carcinomatosis in rats.
  • EXPERIMENTAL DESIGN: BDIX rats with macroscopic peritoneal tumors received cisplatin administered as intravenous injection (IV), conventional intraperitoneal injection (IP), or sustained intraperitoneal injection of cisplatin given in a large volume of solvent for maintaining IAP for 1 hour.
  • IAP, in comparison with IV or conventional IP injections, resulted in the increased concentration and depth of diffusion of platinum into diaphragm and peritoneal tumor nodules.
  • Consequently, IAP treatment induced an extended survival of rats treated at an advanced stage of carcinomatosis.
  • CONCLUSIONS: Intraperitoneal chemotherapy with increased IAP, in comparison with conventional IP or IV chemotherapy, improved the tumor accumulation and the antitumor effect of cisplatin in rats bearing advanced peritoneal carcinomatosis.
  • [MeSH-major] Abdomen / physiology. Antineoplastic Agents / pharmacokinetics. Carcinoma / pathology. Cisplatin / pharmacokinetics. Peritoneal Neoplasms / pathology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2001 Feb;27(1):59-64 [11237494.001]
  • [Cites] J Neurooncol. 2005 May;73(1):57-69 [15933820.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):762-4 [12610170.001]
  • [Cites] Lancet Oncol. 2003 May;4(5):277-83 [12732164.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):835-48 [14567035.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:196-203 [14656280.001]
  • [Cites] Br J Cancer. 2003 Dec;89 Suppl 3:S3-8 [14661040.001]
  • [Cites] World J Surg. 2004 May;28(5):451-6 [15085402.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):806-13 [15510161.001]
  • [Cites] Fed Proc. 1975 Oct;34(11):2031-7 [1175798.001]
  • [Cites] Cancer Treat Rep. 1978 Jan;62(1):1-11 [626987.001]
  • [Cites] Cancer Res. 1979 Aug;39(8):3209-14 [455305.001]
  • [Cites] Int J Cancer. 1985 Aug 15;36(2):273-9 [4018914.001]
  • [Cites] Crit Care Med. 1989 Feb;17(2):118-21 [2914444.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3380-4 [2720692.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(6):389-94 [2311166.001]
  • [Cites] J Appl Physiol (1985). 1991 Jun;70(6):2611-8 [1885456.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1993-5 [1551128.001]
  • [Cites] Gastroenterol Clin Biol. 1992;16(3):215-9 [1582536.001]
  • [Cites] Sci Am. 1994 Jul;271(1):58-65 [8066425.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Arch Surg. 1995 May;130(5):544-7; discussion 547-8 [7748095.001]
  • [Cites] Acta Oncol. 1995;34(3):361-5 [7779424.001]
  • [Cites] J Trauma. 1995 Sep;39(3):519-24; discussion 524-5 [7473918.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1996 Feb;42(1):77-88 [8833669.001]
  • [Cites] Cancer Treat Res. 1996;82:53-63 [8849943.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):596-603 [8862729.001]
  • [Cites] J Trauma. 1997 Nov;43(5):852-5 [9390500.001]
  • [Cites] Int J Cancer. 1999 May 31;81(5):779-84 [10328233.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S15-25 [10357554.001]
  • [Cites] Crit Care Med. 2002 Aug;30(8):1854-8 [12163805.001]
  • (PMID = 16794395.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC1570583
  •  go-up   go-down


48. Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA: Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol; 2005 Jan;12(1):65-71
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of peritoneal carcinomatosis of colorectal origin.
  • BACKGROUND: Peritoneal carcinomatosis of colorectal cancer is probably best treated by cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • Hazard ratios for each of the seven abdominal regions were calculated to determine the influence on survival.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma / secondary. Colorectal Neoplasms / pathology. Mitomycin / therapeutic use. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827780.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


49. Gretschel S, Siegel R, Estévez-Schwarz L, Hünerbein M, Schneider U, Schlag PM: Surgical strategies for gastric cancer with synchronous peritoneal carcinomatosis. Br J Surg; 2006 Dec;93(12):1530-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategies for gastric cancer with synchronous peritoneal carcinomatosis.
  • BACKGROUND: Gastric cancer frequently spreads to the peritoneal cavity.
  • The sensitivity of abdominal ultrasonography, computed tomography (CT) and laparoscopy for detecting peritoneal carcinomatosis was compared.
  • Prognosis was determined according to the stage of peritoneal carcinomatosis and therapeutic procedure adopted.
  • RESULTS: One hundred and ten (16.7 per cent) of 660 patients presented with synchronous peritoneal carcinomatosis.
  • The sensitivity for detecting peritoneal carcinomatosis was 85 per cent for laparoscopy compared with 19 per cent for ultrasonography and 28 per cent for CT.
  • Those with P1 carcinomatosis had improved survival rates after complete resection followed by chemotherapy.
  • CONCLUSION: Laparoscopy improves the detection and classification of peritoneal carcinomatosis, and offers patients with gastric cancer a more individualized and effective therapy.
  • [MeSH-minor] Algorithms. Female. Humans. Male. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Prospective Studies. Sensitivity and Specificity. Survival Rate. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Surg. 2007 May;94(5):642; author reply 642-3 [17443865.001]
  • (PMID = 17051604.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


50. Ströhlein MA, Heiss MM: Intraperitoneal immunotherapy to prevent peritoneal carcinomatosis in patients with advanced gastrointestinal malignancies. J Surg Oncol; 2009 Sep 15;100(4):329-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal immunotherapy to prevent peritoneal carcinomatosis in patients with advanced gastrointestinal malignancies.
  • Prognosis of peritoneal carcinomatosis (PC) from GI tract cancers remains poor.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Gastrointestinal Neoplasms / therapy. Immunotherapy. Peritoneal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19697440.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  • [Number-of-references] 16
  •  go-up   go-down


51. Aarts F, Bleichrodt RP, de Man B, Lomme R, Boerman OC, Hendriks T: The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat. Ann Surg Oncol; 2008 Nov;15(11):3299-307
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat.
  • BACKGROUND: Cytoreductive surgery (CS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) results in limited survival benefit and high morbidity and mortality rates in patients with peritoneal carcinomatosis (PC).
  • HIPEC was performed by a closed abdominal perfusion technique using mitomycin-C during 60 minutes.
  • Anastomotic and abdominal wall strength measurements were performed 3 and 5 days after surgery.
  • Abdominal wall strength in the CS + HIPEC group was significantly (P < .01) lower, at both measuring points, than that in both the CS group and the CS + RIT group.
  • CONCLUSION: As adjuvant to CS, HIPEC showed a decrease in anastomotic and abdominal wall wound strength in a model of PC of CRC, whereas RIT did not.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Colonic Neoplasms / therapy. Hyperthermia, Induced. Mitomycin / therapeutic use. Peritoneal Neoplasms / therapy. Radioimmunotherapy. Wound Healing
  • [MeSH-minor] Abdominal Wall / physiology. Abdominal Wall / surgery. Anastomosis, Surgical. Animals. Chemotherapy, Cancer, Regional Perfusion. Combined Modality Therapy. Disease Models, Animal. Gelatinases / metabolism. Hydroxyproline / metabolism. Injections, Intraperitoneal. Intestines / drug effects. Intestines / surgery. Lutetium / therapeutic use. Male. Rats. Rats, Inbred Strains. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18712445.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin; 5H0DOZ21UJ / Lutetium; EC 3.4.24.- / Gelatinases; RMB44WO89X / Hydroxyproline
  •  go-up   go-down


52. Ströhlein MA, Heiss MM: The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis. Future Oncol; 2010 Sep;6(9):1387-94
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
  • Peritoneal carcinomatosis remains an unsolved medical problem in modern oncologic treatment.
  • Excruciating symptoms such as malignant ascites, ileus, nausea, vomiting, dyspnoea and pain deteriorate the quality of life for affected patients.
  • There is still no effective standard treatment for peritoneal carcinomatosis.
  • Intraperitoneal catumaxomab therapy was shown to be the first effective therapy against accumulation of malignant ascites in patients with peritoneal carcinomatosis of epithelial cancer, reducing the need of paracentesis and prolonging puncture-free survival.
  • This paper reviews the mode of action of catumaxomab and analyzes different fields of local immunotherapy in patients with peritoneal carcinomatosis.
  • Catumaxomab is discussed to be an outstanding option for local control and therapy of peritoneal carcinomatosis, which could be an optimal modular therapy in addition to systemic chemotherapy and surgical tumor resection.
  • [MeSH-major] Antibodies, Bispecific / therapeutic use. Antineoplastic Agents / therapeutic use. Ascites / drug therapy. Carcinoma / drug therapy. Peritoneal Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20919824.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antineoplastic Agents; 0 / catumaxomab
  •  go-up   go-down


53. Nesher E, Greenberg R, Avital S, Skornick Y, Schneebaum S: Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in peritoneal carcinomatosis. Isr Med Assoc J; 2007 Nov;9(11):787-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in peritoneal carcinomatosis.
  • BACKGROUND: Peritoneal carcinomatosis is an advanced form of cancer with poor prognosis that in the past was treated mainly palliatively.
  • Today, the definitive approach to peritoneal surface malignancy involves peritonectomy, visceral resection and perioperative intra-abdominal hyperthermic chemotherapy.
  • OBJECTIVES: To determine whether cytoreductive surgery and intraperitoneal hyperthermic chemotherapy can extend survival, and with minor complications only, in patients with peritoneal carcinomatosis.
  • METHODS: Twenty-two IPHP procedures were performed in 17 patients with peritoneal carcinomatosis in our institution between 1998 and 2007: 6 had pseudomyxoma peritonei, 5 had colorectal carcinoma, 3 had ovarian cancer and 3 had mesotheliomas.
  • After the patient's abdominal temperature reached 41 degrees C, 30-60 mg mitomycin C was circulated intraperitoneally for 1 hour.
  • CONCLUSIONS: IPHP is a safe treatment modality for patients with peritoneal carcinomatosis.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / secondary. Adult. Aged. Colonic Neoplasms / pathology. Combined Modality Therapy. Female. Humans. Male. Mesothelioma / secondary. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18085034.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


54. Molucon-Chabrot C, Isambert N, Benoit L, Zanetta S, Fraisse J, Guilland JC, Royer B, Monin-Baroille P, Flesch M, Fargeot P, Coudert B, Mayer F, Fumoleau P, Chauffert B: Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis. Anticancer Drugs; 2006 Nov;17(10):1211-7
Hazardous Substances Data Bank. EPINEPHRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
  • Intraperitoneal epinephrine above 1 mg/l concentration has been shown to enhance the intratumoral accumulation and antitumor activity of intraperitoneal cisplatin in rats with advanced peritoneal carcinomatosis.
  • The aim of this study was to determine the tolerance of intraperitoneal epinephrine combined with intraperitoneal cisplatin in patients with advanced peritoneal carcinomatosis (17 ovarian cancers, one peritoneal mesothelioma).
  • This work demonstrates for the first time that intraperitoneal epinephrine at sufficient concentration enhances the cisplatin effect and can be safely infused into the peritoneal cavity of patients with peritoneal carcinomatosis.
  • The greatest limitation was abdominal pain and limited intraperitoneal distribution of the peritoneal fluid in this closed-abdomen procedure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma / drug therapy. Cisplatin / administration & dosage. Epinephrine / administration & dosage. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075321.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; YKH834O4BH / Epinephrine
  •  go-up   go-down


55. Capone A, Valle M, Proietti F, Federici O, Garofalo A, Petrosillo N: Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis. J Surg Oncol; 2007 Nov 1;96(6):507-13
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis.
  • BACKGROUND: Peritoneal carcinomatosis is a common evolution of many abdominal and pelvic malignancies.
  • The increasing role of this surgery for the treatment of peritoneal carcinomatosis should strengthen the need for a careful evaluation of possible risk factors for postoperative infections, including the role of colonizing organisms.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bacterial Infections / etiology. Carcinoma / drug therapy. Carcinoma / surgery. Chemotherapy, Adjuvant. Hyperthermia, Induced. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Postoperative Complications

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708508.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


56. Dromain C, Leboulleux S, Auperin A, Goere D, Malka D, Lumbroso J, Schumberger M, Sigal R, Elias D: Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging; 2008 Jan-Feb;33(1):87-93
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT.
  • PURPOSE: To assess and compare the performance of CT and 18F-FDG-PET/CT in the evaluation of peritoneal carcinomatosis (PC).
  • The extent of PC was assessed precisely using the peritoneal cancer index combining the distribution of tumor throughout 11 abdominopelvic regions with a lesion size score.
  • CONCLUSION: The intraperitoneal assessment of the extent of carcinomatosis, necessary to assess prognosis and treatment planning, is not accurate enough with CT and PET/CT imaging.
  • [MeSH-major] Peritoneal Neoplasms / radiography. Peritoneal Neoplasms / radionuclide imaging. Tomography, Emission-Computed. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Contrast Media. Female. Fluorodeoxyglucose F18. Gastrointestinal Neoplasms / pathology. Humans. Iohexol. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17632751.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4419T9MX03 / Iohexol
  •  go-up   go-down


57. Cotton F, Pellet O, Gilly FN, Granier A, Sournac L, Glehen O: MRI evaluation of bulky tumor masses in the mesentery and bladder involvement in peritoneal carcinomatosis. Eur J Surg Oncol; 2006 Dec;32(10):1212-6
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI evaluation of bulky tumor masses in the mesentery and bladder involvement in peritoneal carcinomatosis.
  • AIM: Peritonectomy procedures with intraperitoneal chemohyperthermia are an effective but costly treatment for peritoneal carcinomatosis (PC).
  • METHODS: Three experts retrospectively reviewed abdominal and pelvic MRI from 19 cases of surgically proved PC (ovary: 7; colorectal: 7; gastric: 2; pseudomyxoma peritonei: 2; appendix: 1).
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / secondary. Magnetic Resonance Imaging. Mesentery / pathology. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Contrast Media. Gadolinium. Humans. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / secondary. Intestinal Neoplasms / surgery. Intestines / pathology. Meglumine / analogs & derivatives. Organometallic Compounds. Urinary Bladder / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16762527.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 15G12L5X8K / gadobenic acid; 6HG8UB2MUY / Meglumine; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


58. Hribaschek A, Meyer F, Schneider-Stock R, Pross M, Ridwelski K, Lippert H: Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis. Chemotherapy; 2007;53(6):410-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis.
  • BACKGROUND: Recurrent tumor growth of colorectal carcinoma at the peritoneal site remains an unsolved problem.
  • (1) taxol was applied directly into the abdominal cavity, intraperitoneally or intravenously, immediately following intraperitoneal tumor cell transfer;.
  • Thirty days after tumor cell transfer, rats were sacrificed, and tumor weight, number of nodes (at greater omentum and peritoneum) and ascites volume were determined.
  • RESULTS: Taxol generated a significant inhibitory effect on peritoneal tumor growth.
  • CONCLUSION: Taxol appears to be a potential chemotherapeutic drug providing a significant effect in the therapeutic management of peritoneal carcinomatosis under experimental conditions.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Disease Models, Animal. Liver Neoplasms, Experimental / drug therapy. Paclitaxel / administration & dosage. Peritoneal Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17952000.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


59. Gros SJ, Dohrmann T, Rawnaq T, Kurschat N, Bouvet M, Wessels J, Hoffmann RM, Izbicki JR, Kaifi JT: Orthotopic fluorescent peritoneal carcinomatosis model of esophageal cancer. Anticancer Res; 2010 Oct;30(10):3933-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orthotopic fluorescent peritoneal carcinomatosis model of esophageal cancer.
  • MATERIALS AND METHODS: Nude mice were orthotopically injected in the abdominal esophagus with stably transfected GFP-PT1590 cells.
  • RESULTS: Fifty percent of animals developed extensive peritoneal spread without a distinct primary tumor at the injection site.
  • Although injection of the esophageal carcinoma cell line GFP-PT1590 did not lead to primary esophageal tumor development at the site of injection, 50% of the mice developed extensive peritoneal spread, as well as lymph node and organ metastasis.
  • CONCLUSION: The orthotopic cell injection model resulted in peritoneal carcinomatosis of esophageal adenocarcinoma, which could be visualized in real time using fluorescence imaging.
  • [MeSH-major] Carcinoma / pathology. Disease Models, Animal. Esophageal Neoplasms / pathology. Green Fluorescent Proteins / biosynthesis. Molecular Imaging / methods. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Cell Line, Tumor. Fluorescence. Humans. Mice. Mice, Nude. Neoplasm Metastasis. Neoplasm Transplantation. Transfection. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21036705.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


60. De Gaetano AM, Calcagni ML, Rufini V, Valenza V, Giordano A, Bonomo L: Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls. Abdom Imaging; 2009 May-Jun;34(3):391-402
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls.
  • Early diagnosis of peritoneal spread in malignant disease is essential to prevent unnecessary laparotomies and to select the patients in whom complete cytoreduction is feasible.
  • Although anatomic imaging is the mainstay for evaluating peritoneal seeding, small neoplastic implants can be difficult to detect with CT and MR imaging.
  • FDG PET-CT has the potential to improve detection of peritoneal metastases as lesion conspicuity is high at PET due to low background activity and fused PET-CT offers the combined benefits of anatomic and functional imaging.
  • Distinct patterns appear to predict the presence of either nodular or diffuse peritoneal pathology.
  • FDG PET-CT adds to conventional imaging in the detection and staging of peritoneal carcinomatosis and is a useful diagnostic tool in monitoring response to therapy and in long term follow-up.
  • [MeSH-major] Ovarian Neoplasms / radiography. Ovarian Neoplasms / radionuclide imaging. Peritoneal Neoplasms / radiography. Peritoneal Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Female. Fluorodeoxyglucose F18. Humans. Intestine, Large / radiography. Intestine, Large / radionuclide imaging. Intestine, Small / radiography. Intestine, Small / radionuclide imaging. Ovary / radiography. Ovary / radionuclide imaging. Peritoneum / radiography. Peritoneum / radionuclide imaging. Radiopharmaceuticals. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18446399.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 27
  •  go-up   go-down


61. Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM: Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res; 2009;28:18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis.
  • Peritoneal carcinomatosis (PC) from epithelial tumors is a fatal diagnosis without efficient treatment.
  • [MeSH-major] Antibodies, Bispecific / therapeutic use. Antibodies, Monoclonal / therapeutic use. Peritoneal Neoplasms / immunology. Peritoneal Neoplasms / therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jul;83(2):261-6 [10901380.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3899-905 [17606723.001]
  • [Cites] Eur J Surg Oncol. 2001 Mar;27(2):125-34 [11289746.001]
  • [Cites] Br J Cancer. 2001 Jul 20;85(2):152-6 [11461069.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2526-34 [11588051.001]
  • [Cites] Semin Oncol. 2001 Dec;28(6 Suppl 18):3-11 [11774200.001]
  • [Cites] Cancer Immunol Immunother. 2002 Dec;51(11-12):621-9 [12439607.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2234-43 [14676800.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):219-28 [15050953.001]
  • [Cites] J Clin Oncol. 1986 Jul;4(7):1135-47 [3522820.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] Oncology. 2000 Feb;58(2):96-107 [10705236.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2201-9 [10829039.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1120-8 [2569032.001]
  • [Cites] J Pathol. 1990 Nov;162(3):255-60 [2266463.001]
  • [Cites] J Cell Biol. 1994 Apr;125(2):437-46 [8163559.001]
  • [Cites] Hepatogastroenterology. 1994 Apr;41(2):124-9 [8056398.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] J Immunol. 1995 Jul 1;155(1):219-25 [7602098.001]
  • [Cites] Cancer Immunol Immunother. 1995 Jun;40(6):390-6 [7543021.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4409-15 [7545540.001]
  • [Cites] J Natl Cancer Inst. 1995 Oct 4;87(19):1463-9 [7674333.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):884-91 [9041149.001]
  • [Cites] Immunol Today. 1997 Mar;18(3):127-35 [9078685.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):529-34 [10091726.001]
  • [Cites] J Immunol. 1999 Aug 1;163(3):1246-52 [10415020.001]
  • [Cites] Int J Cancer. 2005 Nov 10;117(3):435-43 [15906359.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):128-35 [16404366.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3085-91 [16707606.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):483-8 [16678891.001]
  • [Cites] Br J Surg. 2006 Dec;93(12):1530-5 [17051604.001]
  • [Cites] J Immunol Methods. 2001 Feb 1;248(1-2):149-65 [11223076.001]
  • (PMID = 19216794.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antibodies, Monoclonal; 0 / Epitopes, T-Lymphocyte; 0 / catumaxomab; 0 / ertumaxomab
  • [Other-IDs] NLM/ PMC2644666
  •  go-up   go-down


62. Cavaliere F, Giannarelli D, Valle M, Federici O, Liotta G, Perri P, Di Filippo F, Garofalo A, Ialongo P: Peritoneal carcinomatosis from ovarian epithelial primary: combined aggressive treatment. In Vivo; 2009 May-Jun;23(3):441-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal carcinomatosis from ovarian epithelial primary: combined aggressive treatment.
  • The low extra-abdominal relapse attitude leads to consider the opportunity of treatment intensification combining aggressive cytoreductive surgery with locoregional chemotherapy for FIGO stage III/IV ovarian carcinoma recurrent after the first-line chemotherapy, having still a curative intent.
  • PATIENTS AND METHODS: An "open" intra-abdominal hyperthermic perfusion with 25 mg/m(2)/lt cisplatin of perfusate or 50 mg/m(2)cisplatin plus 15 mg/m(2)doxorubicin was carried out throughout the abdomino-pelvic cavity on 42 patients affected by peritoneal carcinomatosis from ovarian primary, soon after tumor removal en bloc with regional involved peritoneum.
  • [MeSH-major] Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454512.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


63. Zinzindohoué F, Glehen O, Ferraz JM, Gilly F, Cuqnenc PH: [Surgical treatment of peritoneal carcinomatosis with reduction surgery and perioperative chemotherapy]. Rev Prat; 2008 May 15;58(9):940-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of peritoneal carcinomatosis with reduction surgery and perioperative chemotherapy].
  • [Transliterated title] Traitement des carcinoses péritonéales par chirurgie de réduction chimiothérapie périopératoire.
  • So far, peritoneal carcinomatosis had been considered as the last progression stage of intra-abdominal cancers, and thus without any therapeutic recourse.
  • The main indications are peritoneal carcinomatosis on colorectal cancer, stomach cancer, ovarian cancer, pseudomyxoma and mesothelioma.
  • The treatment can also be initiated secondarily, if carcinomatosis is detected during a procedure performed in a center where this type of treatment is not provided.
  • [MeSH-major] Carcinoma / therapy. Peritoneal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672658.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


64. Mura G, Framarini M, Vagliasindi A, Cavaliere D, Tauceri F, Solfrini G, Milandria C, Verdecchia GM: [Preliminary experience with hyperthermic intraperitoneal chemo-perfusion with oxaliplatin for the treatment of peritoneal carcinomatosis due to colorectal carcinoma]. Chir Ital; 2007 Mar-Apr;59(2):217-23
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preliminary experience with hyperthermic intraperitoneal chemo-perfusion with oxaliplatin for the treatment of peritoneal carcinomatosis due to colorectal carcinoma].
  • [Transliterated title] Espenrenza preliminare di trattamento della carcinosi peritoneale da carinoma colorettale mediante chemio-ipertermia ntaperitoneale con oxaliplatino.
  • Peritoneal carcinomatosis is the first cause of death after surgery for abdominal cancer, with a mean survival of 7 months.
  • Over the period from 2004 to January 2006, 86 patients were operated on for peritoneal carcinomatosis at the Division of Surgical Oncology, Forli, Italy.
  • The remaining patients are alive and free from peritoneal disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / therapy. Chemotherapy, Cancer, Regional Perfusion / methods. Colorectal Neoplasms / therapy. Hyperthermia, Induced. Organoplatinum Compounds / therapeutic use. Peritoneal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17500178.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


65. Franiel T, Diederichs G, Engelken F, Elgeti T, Rost J, Rogalla P: Multi-detector CT in peritoneal carcinomatosis: diagnostic role of thin slices and multiplanar reconstructions. Abdom Imaging; 2009 Jan-Feb;34(1):49-54
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-detector CT in peritoneal carcinomatosis: diagnostic role of thin slices and multiplanar reconstructions.
  • BACKGROUND: In order to investigate whether 1-mm thin slices and multiplanar reconstructions (MPRs) of multi-detector computed tomography (CT) datasets interpreted in addition to isotropic 5-mm thick slices in one session improve the detection of peritoneal carcinomatosis.
  • METHODS: The abdominal CT datasets of 44 patients with histologically proven tumors of the abdomen or pelvis were retrospectively evaluated for peritoneal carcinomatosis by four radiologists with variable experience (radiologist 1: >or=10 years, radiologists 2 and 3: 1.5 years, radiologist 4: 0.5 years).
  • CONCLUSIONS: While 5-mm slices are sufficient for the detection of peritoneal carcinomatosis, 1-mm slices and MPRs can improve sensitivity and diagnostic confidence.
  • [MeSH-major] Carcinoma / radiography. Peritoneal Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18264738.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 4419T9MX03 / Iohexol; 712BAC33MZ / iopromide
  •  go-up   go-down


66. Sideris L, Mitchell A, Drolet P, Leblanc G, Leclerc YE, Dubé P: Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix. Can J Surg; 2009 Apr;52(2):135-41
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.
  • BACKGROUND: Peritoneal carcinomatosis (PC) originating in the appendix is a rare disease for which the long-term prognosis is poor.
  • We used Ronnett's classification for tumour grading (disseminated peritoneal adenomucinosis = grade 0, peritoneal mucinous carcinomatosis with intermediate features = grade 1 and peritoneal mucinous carcinomatosis = grade 2).
  • The overall complication rate was 36%, including fistulas (16%), intra-abdominal abscesses (12%) and hemorrhage (9%).
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Antineoplastic Agents / administration & dosage. Appendiceal Neoplasms / pathology. Hyperthermia, Induced. Peritoneal Neoplasms / therapy

  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Anat Pathol. 2005 Nov;12(6):291-311 [16330927.001]
  • [Cites] Jpn J Clin Oncol. 2005 Sep;35(9):531-5 [16027146.001]
  • [Cites] J Oncol Pharm Pract. 2005 Sep;11(3):111-9 [16390599.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1287-92 [16622455.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):551-9 [16699309.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):607-13 [16621432.001]
  • [Cites] Cancer Invest. 2006 Mar;24(2):154-9 [16537184.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] Langenbecks Arch Surg. 1999 Dec;384(6):576-87 [10654274.001]
  • [Cites] J Chir (Paris). 1999 Dec;136(6):341-7 [10675825.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):1006-15 [10931042.001]
  • [Cites] Ann Oncol. 2000 Nov;11(11):1477-83 [11142489.001]
  • [Cites] Gynecol Obstet Invest. 2001;51(2):73-80 [11223697.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):458-63 [11260116.001]
  • [Cites] Eur J Cancer. 2001 May;37(8):979-84 [11334722.001]
  • [Cites] Int J Surg Investig. 2000;1(5):431-9 [11341599.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):85-91 [11443613.001]
  • [Cites] Br J Surg. 2001 Aug;88(8):1130 [11488802.001]
  • [Cites] Int J Cancer. 2001 Oct 20;96(5):297-304 [11582582.001]
  • [Cites] Postgrad Med J. 2002 Mar;78(917):170-2 [11884702.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):267-72 [11886004.001]
  • [Cites] Tumori. 2002 Sep-Oct;88(5):370-5 [12487553.001]
  • [Cites] Gastroenterol Clin Biol. 2003 Apr;27(4):407-12 [12759682.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):413-8 [12911716.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):682-8 [14511618.001]
  • [Cites] Eur J Surg Oncol. 2004 Apr;30(3):280-5 [15028309.001]
  • [Cites] Br J Surg. 2004 Apr;91(4):455-6 [15048746.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1558-65 [15367418.001]
  • [Cites] Ugeskr Laeger. 2004 Aug 23;166(35):2979-81 [15387006.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):772-9 [2820671.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3380-4 [2720692.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Dec;25(12):1857-66 [2632267.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):109-11 [8129480.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):591-603 [8179074.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Cancer Treat Res. 1996;81:105-19 [8834579.001]
  • [Cites] Eur J Cancer. 1996 Sep;32A(10):1727-33 [8983281.001]
  • [Cites] J Cancer Res Clin Oncol. 1997;123(1):6-12 [8996534.001]
  • [Cites] Eur J Surg Oncol. 1997 Aug;23(4):317-21 [9315060.001]
  • [Cites] Rev Med Interne. 1997;18(10):769-75 [9500010.001]
  • [Cites] Semin Surg Oncol. 1998 Apr-May;14(3):254-61 [9548609.001]
  • [Cites] Anat Pathol. 1997;2:197-226 [9575376.001]
  • [Cites] Gastroenterologist. 1998 Jun;6(2):147-50 [9660531.001]
  • [Cites] Br J Surg. 1999 Jun;86(6):842 [10419331.001]
  • [Cites] Ned Tijdschr Geneeskd. 1999 Sep 11;143(37):1863-8 [10526600.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):300-8 [15650641.001]
  • [Cites] Clin Colorectal Cancer. 2005 Jan;4(5):296-9 [15663831.001]
  • [Cites] Zentralbl Chir. 2005 Apr;130(2):177-80 [15849666.001]
  • [Cites] Acta Chir Belg. 2005 Apr;105(2):127-33 [15906901.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):812-6 [15966210.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):69-76 [16389186.001]
  • (PMID = 19399209.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 50SG953SK6 / Mitomycin; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2663512
  •  go-up   go-down


67. Bevanda M, Orsolic N, Basic I, Vukojevic K, Benkovic V, Horvat Knezevic A, Lisicic D, Dikic D, Kujundzic M: Prevention of peritoneal carcinomatosis in mice with combination hyperthermal intraperitoneal chemotherapy and IL-2. Int J Hyperthermia; 2009 Mar;25(2):132-40
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of peritoneal carcinomatosis in mice with combination hyperthermal intraperitoneal chemotherapy and IL-2.
  • PURPOSE: The purpose of this study was to investigate the effect of local chemoimmunotherapy and hyperthermal intraperitoneal chemotherapy (HIPEC) in a mouse model of induced peritoneal carcinomatosis.
  • MATERIAL AND METHODS: Peritoneal carcinomatosis in mice was produced by intraperitoneal implantation of MCa cells (5 x 10(3)).
  • Interleukin-2 (4.1 x 10(4) IU/mouse) was injected into the abdominal cavity of mice at day 7 and 3 before implantation of tumour cells.
  • RESULTS: Combined treatment with Interleukin-2 (IL-2) and cytostatics (5-FU, CIS or MIT) significantly affected the development of peritoneal carcinomatosis and increased the survival of mice (ILS% - 37 degrees C = 29.88, 199.32, and 108.52, ILS% - 43 degrees C = 62.69, 260.50, and 178.05, respectively).
  • CONCLUSION: We would like to stress that treatment with IL-2 prior to tumour diagnosis is not clinically practical, rather, the manuscript attempts to describe an experimental proof of principle.
  • Results suggest the synergistic effect of hyperthermia, chemotherapy and immunotherapy; IL-2 significantly increases antitumor activity of hyperthermic chemotherapy and survival rate of mice with peritoneal carcinomatosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / therapy. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced / methods. Interleukin-2 / therapeutic use. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Animals. Body Temperature. Combined Modality Therapy. Disease Models, Animal. Female. Humans. Immunotherapy / methods. Male. Mice. Mice, Inbred CBA. Neoplasm Transplantation. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19337913.001).
  • [ISSN] 1464-5157
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2
  •  go-up   go-down


68. Yang XJ, Li Y, al-shammaa Hassan AH, Yang GL, Liu SY, Lu YL, Zhang JW, Yonemura Y: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. Ann Surg Oncol; 2009 Feb;16(2):345-51
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.
  • We evaluated the perioperative safety profile and efficacy of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in 21 patients with peritoneal carcinomatosis (PC) from gastrointestinal and gynecological cancers.
  • Twenty-one patients with PC (12 gastric cancer, 5 colorectal cancer, 2 ovarian cancer, 1 pseudomyxoma peritonei, 1 malignant mesothelioma) were treated with CRS + HIPEC with hydroxycamptothecin 20 mg and mitomycin C 30 mg in 12,000 mL of normal saline at 43 +/- .5 degrees C for 60 to 90 minutes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adenocarcinoma / therapy. Adult. Aged. Camptothecin / administration & dosage. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Mesothelioma / mortality. Mesothelioma / pathology. Mesothelioma / therapy. Middle Aged. Mitomycin / administration & dosage. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Prognosis. Stomach Neoplasms / mortality. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy. Survival Rate

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018599.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


69. Glehen O, Cotte E, Brigand C, Arvieux C, Sayag-Beaujard AC, Gilly FN: [Therapeutic innovations in the management of peritoneal carcinomatosis from digestive origin: cytoreductive surgery and intraperitoneal chemotherapy]. Rev Med Interne; 2006 May;27(5):382-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic innovations in the management of peritoneal carcinomatosis from digestive origin: cytoreductive surgery and intraperitoneal chemotherapy].
  • [Transliterated title] Nouveautés thérapeutiques dans la prise en charge des carcinoses péritonéales d'origine digestive: chirurgie de cytoréduction et chimiothérapie intrapéritonéale.
  • PURPOSE: Peritoneal carcinomatosis and particularly those from digestive origin has long been considered as an automatically terminal disease in abdominal cancer patients.
  • It may allow prolonged survival and cure for patients with pseudomyxoma peritonei, peritoneal mesothelioma, carcinomatosis from colorectal or gastric cancer.
  • Qualitative and quantitative prognostic indicators are needed to assess a patient's eligibility, including tumor histopathology, assessment of carcinomatosis extent or completeness of cytoreduction which appears to be the most important.
  • PERSPECTIVES: Combination of cytoreductive surgery with perioperative intraperitoneal chemotherapy appears to be an adapted therapeutic approach for patients strictly selected, with peritoneal carcinomatosis.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236392.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


70. Yan TD, Sim J, Morris DL: Selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol; 2007 Jun;14(6):1807-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and perioperative intraperitoneal chemotherapy.
  • BACKGROUND: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy has been suggested as a treatment option for patients with colorectal peritoneal carcinomatosis.
  • Patients with good performance status, low volume of peritoneal disease, and absence of extra-abdominal metastases are more likely to benefit from the combined treatment.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Colonic Neoplasms / surgery. Neoadjuvant Therapy. Patient Selection. Peritoneal Neoplasms / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Diagnostic Imaging. Humans. Injections, Intraperitoneal. Neoplasm Staging. Perioperative Care. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17342564.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 76
  •  go-up   go-down


71. Wang Y, Gong C, Yang L, Wu Q, Shi S, Shi H, Qian Z, Wei Y: 5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice. BMC Cancer; 2010;10:402
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice.
  • BACKGROUND: Colorectal peritoneal carcinomatosis (CRPC) is a common form of systemic metastasis of intra-abdominal cancers.
  • 5-FU-hydrogel was subsequently injected into abdominal cavity in mice with CT26 cancer cells peritoneal dissemination.
  • The results showed that the hydrogel delivery system prolonged the release of methylene blue; the 5-FU-hydrogel significantly inhibited the peritoneal dissemination and growth of CT26 cells.
  • CONCLUSIONS: Our data indicate that the 5-FU-hydrogel system can be considered as a new strategy for peritoneal carcinomatosis, and the hydrogel may provide a potential delivery system to load different chemotherapeutic drugs for peritoneal carcinomatosis of cancers.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Drug Delivery Systems. Fluorouracil / therapeutic use. Hydrogels. Peritoneal Neoplasms / drug therapy. Polymers / chemistry

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biomed Mater Res. 2000 May;50(2):171-7 [10679681.001]
  • [Cites] Biomed Mater. 2009 Apr;4(2):025002 [19208940.001]
  • [Cites] J Surg Oncol. 2002 Jan;79(1):46-61 [11754377.001]
  • [Cites] Adv Drug Deliv Rev. 2002 Jan 17;54(1):99-134 [11755708.001]
  • [Cites] Br J Surg. 2002 Dec;89(12):1545-50 [12445064.001]
  • [Cites] Eur J Pharm Biopharm. 2004 Sep;58(2):409-26 [15296964.001]
  • [Cites] Cancer. 1989 Jan 15;63(2):364-7 [2910444.001]
  • [Cites] Nature. 1997 Aug 28;388(6645):860-2 [9278046.001]
  • [Cites] Nature. 1999 Jun 24;399(6738):766-9 [10391240.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):4011-9 [16921055.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):128-33 [17072675.001]
  • [Cites] Ann Surg Oncol. 2007 Jun;14(6):1818-24 [17356950.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2281-8 [17503156.001]
  • [Cites] J Biomed Mater Res B Appl Biomater. 2008 Jan;84(1):165-75 [17455282.001]
  • [Cites] J Biomed Mater Res A. 2008 Apr;85(1):36-46 [17688254.001]
  • [Cites] Ann Surg Oncol. 2008 Jun;15(6):1800-1; author reply 1802-3 [18196342.001]
  • [Cites] Int J Biol Macromol. 2008 Jul 1;43(1):32-6 [17950453.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2426-32 [18521686.001]
  • [Cites] Int J Pharm. 2009 Jan 5;365(1-2):89-99 [18793709.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):681-5 [19103728.001]
  • [Cites] J Control Release. 2001 Jun 15;73(2-3):315-27 [11516508.001]
  • (PMID = 20678220.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Hydrogels; 0 / Polyesters; 0 / Polymers; 0 / poly(ethylene glycol)-poly(caprolactone)-poly(ethylene glycol); 30IQX730WE / Polyethylene Glycols; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2920883
  •  go-up   go-down


72. Peter S, Eltoum I, Eloubeidi MA: EUS-guided FNA of peritoneal carcinomatosis in patients with unknown primary malignancy. Gastrointest Endosc; 2009 Dec;70(6):1266-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EUS-guided FNA of peritoneal carcinomatosis in patients with unknown primary malignancy.
  • The role of EUS-guided FNA in the diagnosis of peritoneal carcinomatosis has not been well studied.
  • OBJECTIVE: We aimed to determine the feasibility and success in sampling lesions in the peritoneum suspicious for carcinomatosis without a primary source.
  • PATIENTS: Consecutive patients who underwent EUS-guided FNA of peritoneal deposits.
  • RESULTS: During a span of 3 years, 4 patients underwent transgastric or transduodenal EUS-guided FNA of peritoneal lesions with a curvilinear echoendoscope.
  • All of these lesions were imaged by abdominal CT scan.
  • Four passes were performed per case, and the diagnosis was achieved on a median of 2 passes (range 1-4).
  • CONCLUSIONS: Transgastric or transduodenal EUS-guided FNA for peritoneal carcinomatosis is feasible and safe.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Carcinoma / pathology. Endosonography. Neoplasms, Unknown Primary / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2011 Jan;73(1):188-9 [21184887.001]
  • (PMID = 19640520.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Sugarbaker PH: Strategies for the prevention and treatment of peritoneal carcinomatosis from gastrointestinal cancer. Cancer Invest; 2005;23(2):155-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies for the prevention and treatment of peritoneal carcinomatosis from gastrointestinal cancer.
  • BACKGROUND: Peritoneal surface malignancy can result from full thickness invasion of gastrointestinal cancer through the bowel wall or from dissemination of cancer cells from the trauma of cancer surgery.
  • METHODS: An aggressive approach to peritoneal surface malignancy involves peritonectomy procedures, perioperative intraperitoneal chemotherapy and knowledgeable patient selection.
  • The clinical assessments necessary for valid clinical judgements include the cancer histopathology (invasive vs. expansive progression), the preoperative abdominal and pelvic CT, the peritoneal cancer index and the completeness of cytoreduction score.
  • RESULTS: In a series of phase II studies, appendiceal tumors with peritoneal seeding became the paradigm for success with an 85% long-term survival in selected patients.
  • Carcinomatosis from colon cancer had an overall 5-year survival of 50% with selected patients.
  • In all malignancies, early aggressive treatment of minimal peritoneal surface dissemination showed the greatest benefit.
  • CONCLUSIONS: Oncologists must accept responsibility for knowledgeable management of peritoneal surface dissemination of cancer because a curative approach has been demonstrated in both phase II studies and phase III studies.
  • Surgical interventions combined with perioperative intraperitoneal chemotherapy in diseases where peritoneal surface spread occurs must be considered a treatment option.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / prevention & control. Colonic Neoplasms / pathology. Gastrointestinal Neoplasms / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / prevention & control
  • [MeSH-minor] Humans. Infusions, Parenteral. Intraoperative Period. Neoplasm Invasiveness. Neoplastic Cells, Circulating. Patient Selection. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15813509.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


74. Cho C, Wust P, Hildebrandt B, Issels RD, Sehouli J, Kerner T, Deja M, Budach V, Gellermann J: Regional hyperthermia of the abdomen in conjunction with chemotherapy for peritoneal carcinomatosis: evaluation of two annular-phased-array applicators. Int J Hyperthermia; 2008 Aug;24(5):399-408

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional hyperthermia of the abdomen in conjunction with chemotherapy for peritoneal carcinomatosis: evaluation of two annular-phased-array applicators.
  • BACKGROUND: Peritoneal carcinomatosis is a stage of gynecological and gastrointestinal malignancies with poor prognosis.
  • METHODS: Forty-five patients with peritoneal carcinomatosis (with or without liver metastases) in colorectal cancer (CRC) (n = 16), ovarian cancer (OC) (n = 17), or gastric/pancreatic/biliary cancer (n = 12) underwent standard chemotherapy and regional hyperthermia.
  • RESULTS: Abdominal regional hyperthermia was well tolerated, with acceptable acute discomfort and no long-term morbidity.
  • CONCLUSIONS. The SIGMA-60 and SIGMA-Eye/MR applicators are feasible for abdominal heating and have low toxicity.
  • [MeSH-major] Abdomen. Hyperthermia, Induced / instrumentation. Hyperthermia, Induced / methods. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Biliary Tract Neoplasms / therapy. Colorectal Neoplasms / therapy. Combined Modality Therapy. Female. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Male. Middle Aged. Ovarian Neoplasms / therapy. Pancreatic Neoplasms / therapy. Stomach Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18608591.001).
  • [ISSN] 1464-5157
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


75. Samel S, Löhr M: Targeted intraabdominal chemotherapy for peritoneal carcinomatosis. Cancer Treat Res; 2007;134:469-82
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted intraabdominal chemotherapy for peritoneal carcinomatosis.
  • The prognosis of peritoneal spread from gastrointestinal cancer and subsequent malignant ascites is poor, and current medical treatments available are mostly ineffective.
  • Adult Balb/c mice were inoculated intraperitoneally (i.p.) with 1 x 10(6) colon cancer cells, previously transfected with GFP to emit a stable green fluorescence, by injection into the left lower abdominal quadrant.
  • Peritoneal tumour volume and tumour viability were assessed 10 days after tumour inoculation by means of fluorescence microscopy, spectroscopy and histology.
  • These results suggest that targeted i.p. chemotherapy using a combination of a prodrug and its converting enzyme may be a successful treatment strategy for peritoneal spread from colorectal cancer.
  • In summary, by using GFP-transfected colon 26 tumour cells in mice we established a well reproducible animal model of metastatic peritoneal cancer.
  • Fluorescent imaging of GFP-transfected tumour was used to demonstrate tumour distribution in the peritoneal cavity and to estimate tumour growth and tumour response to treatment in this model.
  • The application of Capcell and ifosfamide into the peritoneal cavity is a safe and well tolerated procedure in animal models and may help to target chemotherapeutic agents specifically at metastatic peritoneal cancer.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Carcinoma / drug therapy. Cellulose / analogs & derivatives. Drug Delivery Systems. Ifosfamide / administration & dosage. Peritoneal Neoplasms / drug therapy. Prodrugs / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633075.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Prodrugs; 9004-34-6 / Cellulose; 9032-43-3 / cellulose sulfate; 9035-51-2 / Cytochrome P-450 Enzyme System; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


76. Gómez Portilla A, Cendoya I, López de Tejada I, Olabarría I, Martínez de Lecea C, Magrach L, Gil A, Echevarría J, Valdovinos M, Larrabide I: Peritoneal carcinomatosis of colorectal origin. Current treatment. Review and update. Rev Esp Enferm Dig; 2005 Oct;97(10):716-37
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal carcinomatosis of colorectal origin. Current treatment. Review and update.
  • The high incidence of abdominal dissemination; the poor prognosis of these patients, with median survival consistently ranging from 5 to 9 months in all studies of peritoneal carcinomatosis from colorectal cancer; the failure of adjuvant systemic chemotherapy treatment with a maximal survival of 18 months despite the development of new cytostatic drugs, and new combinations of use, make it crucial to search for and develop new treatment strategies.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351464.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 111
  •  go-up   go-down


77. Adali E, Dulger C, Kolusari A, Kurdoglu M, Yildizhan R: Pelvic-peritoneal tuberculosis simulating peritoneal carcinomatosis: high clinical suspicion and a minimally invasive procedure. Arch Gynecol Obstet; 2009 Nov;280(5):867-8
Genetic Alliance. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic-peritoneal tuberculosis simulating peritoneal carcinomatosis: high clinical suspicion and a minimally invasive procedure.
  • Peritoneal tuberculosis (TB) is still a major health problem in developing countries.
  • We describe a 26-year-old woman with peritoneal TB presenting with lower abdominal pain and distention, weight loss, and night sweats.
  • There are no pathognomonic clinical, laboratory, or radiologic findings for peritoneal TB.
  • Therefore, it can be easily confused with peritoneal carcinomatosis and advanced ovarian carcinoma.
  • Adenosine deaminase activity in ascitic fluid combined with a high clinic suspicion is an effective and minimally invasive procedure for the differential diagnosis of pelvic-peritoneal TB simulating peritoneal carcinomatosis, and may obviate the need for unnecessary extensive surgery and rapidly initiate appropriate therapy.
  • [MeSH-major] Peritoneal Neoplasms / diagnosis. Peritonitis, Tuberculous / diagnosis
  • [MeSH-minor] Adenosine Deaminase / analysis. Adult. Ascitic Fluid / enzymology. CA-125 Antigen / blood. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19565253.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-125 Antigen; EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


78. Gómez Portilla A, Cendoya I, Olabarría I, Martínez de Lecea C, Gómez Martínez de Lecea C, Gil A, Martín E, Muriel J, Magrach L, Romero E, Lirola A, Guede N, Moraza N, Fernández E, Kvadatze M, Valdovinos M, Larrabide I, Ruiz de Alegría N, Fernández JL, Castillo C, Rua O, Ulibarrena MA: The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis. Rev Esp Enferm Dig; 2009 Feb;101(2):97-102, 103-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
  • PH Sugarbaker, challenging oncological orthodoxy, considered carcinomatosis to be a locoregional stage of the disease that was still susceptible to treatment with curative intent.
  • The macroscopic disease treated by maximum radical oncological cytoreductive surgery (through the peritonectomies described by him), followed by treatment of the residual microscopic disease with the direct intra-abdominal application of intraoperative chemotherapy with locoregional intensification, modulated by hyperthermia and early normothermic postoperative intra-abdominal chemotherapy.
  • Using this new therapeutic regimen, known as "Sugarbaker s Protocol", his group has reported 45% survival rates in carcinomatosis of colorectal origin at 5 years, and, in selected groups of patients, 50% survival rates at 5 years.
  • Various European groups have replied to these main criticisms confirming the good results that this new therapeutic alternative offers for patients with carcinomatosis of colorectal origin.
  • MATERIAL AND METHODS: All the articles published in the English language by European groups in the world s medical literature have been reviewed using the Pubmed-MEDLINE database to identify the relevant articles related to the treatment of carcinomatosis of colorectal origin using cytoreduction and intraperitoneal chemotherapy from January 1980 to January 2008.
  • At the same time, two new transcendental European contributions have been made in which the possibility has been considered of combined simultaneous treatment for patients with hepatic metastases and carcinomatosis, and the introduction, as a selection factor, of patients responsive to intravenous induction chemotherapy within the regimen of sandwich treatment (with systemic neoadjuvant and adjuvant chemotherapy) complementary to intraperitoneal chemotherapy.
  • CONCLUSIONS: The results obtained by European groups using "Sugarbaker s protocol" and "Elias protocol" with oxaliplatin compel us to request that these treatments be considered by all professionals involved in the treatment of patients with colorectal carcinomatosis as the best treatment currently available for this condition.
  • A validation of this treatment will change, in the future, the dogmatic consideration of carcinomatosis as an incurable disease stage.
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant / statistics & numerical data. Clinical Trials, Phase III as Topic / statistics & numerical data. Combined Modality Therapy. Europe / epidemiology. Fluorouracil / administration & dosage. Humans. Hyperthermia, Induced. Infusions, Parenteral. Liver Neoplasms / secondary. Multicenter Studies as Topic / statistics & numerical data. Neoadjuvant Therapy / statistics & numerical data. Organoplatinum Compounds / administration & dosage. Randomized Controlled Trials as Topic / statistics & numerical data. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19335045.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 54
  •  go-up   go-down


79. Hagendoorn J, van Lammeren G, Boerma D, van der Beek E, Wiezer MJ, van Ramshorst B: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal and gastrointestinal origin shows acceptable morbidity and high survival. Eur J Surg Oncol; 2009 Aug;35(8):833-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal and gastrointestinal origin shows acceptable morbidity and high survival.
  • BACKGROUND: Peritoneal carcinomatosis from colorectal origin carries a poor prognosis.
  • Recent clinical studies show that cytoreductive surgery (CS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival of selected patients with a colorectal carcinoma and isolated peritoneal carcinomatosis in the absence of extra-abdominal metastases.
  • All had peritoneal carcinomatosis originating from primary colorectal, cecal, appendiceal, and gastric tumors.
  • The overall morbidity was 43%, including extended gastroparesis (11%), anastomotic failure (11%) and intra-abdominal abscess (9%).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Colorectal Neoplasms / pathology. Gastrointestinal Neoplasms / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019619.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


80. Cerretani D, Nencini C, Urso R, Giorgi G, Marrelli D, De Stefano A, Pinto E, Cioppa T, Nastri G, Roviello F: Pharmacokinetics of mitomycin C after resection of peritoneal carcinomatosis and intraperitoneal chemohyperthermic perfusion. J Chemother; 2005 Dec;17(6):668-73
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of mitomycin C after resection of peritoneal carcinomatosis and intraperitoneal chemohyperthermic perfusion.
  • Over the last few years surgery on patients with abdominal malignancies has become more aggressive but the majority of patients present locoregional recurrence as peritoneal dissemination.
  • This paper reports our study of the pharmacokinetics of mitomycin C (MMC) administered by intraperitoneal chemohyperthermic perfusion (ICHP) in patients with peritoneal carcinomatosis.
  • We conclude that ICHP in patients with peritoneal surface malignancies seems to have clinical value since it gives high peritoneal and tumor MMC concentrations with limited systemic exposure and toxicity.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacokinetics. Mitomycin / pharmacokinetics. Peritoneal Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Area Under Curve. Chemotherapy, Cancer, Regional Perfusion. Combined Modality Therapy. Female. Half-Life. Humans. Hypothermia, Induced. Infusions, Parenteral. Male. Metabolic Clearance Rate. Middle Aged. Neoplasm Invasiveness

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16433199.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


81. Yan TD, Morris DL: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care? Ann Surg; 2008 Nov;248(5):829-35
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care?
  • BACKGROUND: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has been demonstrated to have an improved survival over systemic chemotherapy for patients with colorectal peritoneal carcinomatosis (CRPC) in a randomized controlled trial.
  • All patients underwent preoperative chest, abdominal and pelvic computed tomography scans, and positron emission tomography.
  • Three clinicopathologic factors were found to be significant for overall survival: tumor differentiation (P < 0.001), peritoneal cancer index (P = 0.021), and completeness of cytoreduction (P < 0.001).
  • The combined treatment for patients with isolated colorectal peritoneal carcinomatosis should be considered to be the current standard of care.
  • [MeSH-major] Colorectal Neoplasms / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948811.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


82. Orsolić N, Bevanda M, Kujundzić N, Plazonic A, Stajcar D, Kujundzić M: Prevention of peritoneal carcinomatosis in mice by combining hyperthermal intraperitoneal chemotherapy with the water extract from Burr parsley (Caucalis platycarpos L.). Planta Med; 2010 May;76(8):773-9
Hazardous Substances Data Bank. Water .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of peritoneal carcinomatosis in mice by combining hyperthermal intraperitoneal chemotherapy with the water extract from Burr parsley (Caucalis platycarpos L.).
  • The presence of peritoneal carcinomatosis arising from gastrointestinal and gynecologic tumors is associated with a poor prognosis.
  • Animal models of peritoneal carcinomatosis are important in the evaluation of new treatment modalities.
  • The purpose of this study was to investigate the effect of local chemoimmunotherapy and hyperthermal intraperitoneal chemotherapy (HIPEC) in an animal model of induced peritoneal carcinomatosis in the mouse.
  • For induction of peritoneal carcinomatosis, cells from transplantable mammary carcinoma (MCa) were implanted intraperitoneally in CBA mice.
  • kg (-1)) into the abdominal cavity.
  • Immediately after implantation of MCa cells in the abdominal cavity, mice were treated two times with 2 mL of saline that was heated either at 37 degrees C or 43 degrees C (hyperthermal treatment) and cytostatics (doxorubicin 20 mg .
  • CPL increased the life span of mice with peritoneal carcinomatosis without hyperthermal treatment (ILS% = 32.55 %) but showed no effect on the life span of mice with hyperthermal treatment (ILS% = 1.44).
  • Combined treatment with CPL and cytostatics (CIS, DOX, and MIT) significantly affected the development of peritoneal carcinomatosis and increased the survival of mice (ILS% - 37 degrees C = 144.17, 415.46, and 124.13, ILS% - 43 degrees C = 311.42, 200.74, and 138.33, respectively).
  • CPL significantly increases the antitumor activity of the hyperthermic chemotherapy and the survival rate of mice with peritoneal carcinomatosis.
  • The stimulative effect of CPL on immunomodulation may be a possible mechanism which protects mice from developing peritoneal carcinomatosis and reduces the side effects of chemotherapy, increasing the life span of mice.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apiaceae / chemistry. Hyperthermia, Induced. Peritoneal Neoplasms / prevention & control. Plant Extracts / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 20033866.001).
  • [ISSN] 1439-0221
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Plant Extracts; 059QF0KO0R / Water
  •  go-up   go-down


83. Funicelli L, Travaini LL, Landoni F, Trifirò G, Bonello L, Bellomi M: Peritoneal carcinomatosis from ovarian cancer: the role of CT and [¹⁸F]FDG-PET/CT. Abdom Imaging; 2010 Dec;35(6):701-7
Hazardous Substances Data Bank. Iodixanol .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal carcinomatosis from ovarian cancer: the role of CT and [¹⁸F]FDG-PET/CT.
  • PURPOSE: The diagnosis of peritoneal carcinomatosis secondary to ovarian cancer is a real challenge in the cancer imaging field.
  • In this retrospective study, we evaluate the accuracy of Single Detector Computed Tomography (SDCT), Multi Detector Computed Tomography (MDCT), and Positron Emission Tomography-Computed Tomography with F18-fluorodeoxyglucose ([¹⁸F]FDG-PET/CT) in the diagnosis of peritoneal seeding and we evaluate the possible applications of MDCT to predict the complete surgical removal of the peritoneal deposits.
  • METHODS AND MATERIALS: A total of 228 scans (91 SDCT, 89 MDCT, and 48 [¹⁸F]FDG-PET/CT) of patients with peritoneal carcinomatosis secondary to ovarian cancer proved at laparoscopy and confirmed by histopathology were retrospectively reviewed by two independent groups of Radiologists and Nuclear Medicine Physicians for the evaluation of ascites, peritoneal nodules, and omental cake signs.
  • CONCLUSION: From our results, we concluded that MDCT is the technique of choice in the diagnosis of peritoneal seeding, while [¹⁸F]FDG-PET/CT, though showing similar accuracy, remains the most accurate technique for monitoring therapeutic response and disease recurrence.
  • [MeSH-major] Carcinoma / radiography. Carcinoma / radionuclide imaging. Ovarian Neoplasms / radiography. Ovarian Neoplasms / radionuclide imaging. Peritoneal Neoplasms / radiography. Peritoneal Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19784697.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Triiodobenzoic Acids; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 92339-11-2 / iodixanol
  •  go-up   go-down


84. Bijelic L, Yan TD, Sugarbaker PH: Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol; 2007 Aug;14(8):2281-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
  • BACKGROUND: The aim of this study was to analyze the anatomic distribution, timing, and outcomes of recurrent disease after complete cytoreduction and perioperative intraperitoneal chemotherapy (PIC) for peritoneal carcinomatosis of colorectal origin.
  • METHODS: Data regarding all patients who underwent complete cytoreduction and PIC for carcinomatosis from colorectal cancer were extracted from a prospectively collected database.
  • The information regarding recurrent disease found on diagnostic evaluation and/or abdominal exploration was analyzed.
  • Eighteen patients had a localized intra-abdominal recurrence, 10 had diffuse intraperitoneal recurrence, 10 had isolated distant metastases, and 11 had a combination of distant metastases and intra-abdominal recurrence.
  • Four of the 49 patients with recurrences were still alive at the time of last follow-up, and three of them have no evidence of disease 73, 96, and 206 months after the diagnosis of recurrence.
  • CONCLUSIONS: Recurrence is a frequent event after optimal cytoreduction and PIC for carcinomatosis from colorectal cancer.
  • [MeSH-major] Carcinoma / surgery. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Neoplasm Recurrence, Local. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Hyperthermia, Induced. Male. Middle Aged. Mitomycin / administration & dosage. Prospective Studies. Radiography, Abdominal. Reoperation / statistics & numerical data. Survival Analysis. Time Factors. Treatment Failure

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2007 Nov;14(11):3037-9 [17726635.001]
  • (PMID = 17503156.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


85. Liberale G, Elias D, Sideris L, Lasser P, Malka D, Sabourin JC, Pocard M: Inguinal canal as an anatomic sanctuary site of relapse in peritoneal carcinomatosis previously treated with intraperitoneal chemotherapy. J Surg Oncol; 2005 Jul 1;91(1):73-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inguinal canal as an anatomic sanctuary site of relapse in peritoneal carcinomatosis previously treated with intraperitoneal chemotherapy.
  • Early postoperative intraperitoneal chemotherapy (EPIC) and intraoperative peritoneal hypertermic chemotherapy (IPHC) are used in addition with cytoreductive surgery to treat with curative intent peritoneal carcinomatosis arising from colorectal adenocarcinomas.
  • No patient showed evidence of intra-abdominal recurrence at the last follow-up, but one developed pulmonary metastasis.
  • When communicating with the peritoneal cavity, the inguinal canal may act as a sanctuary site for peritoneal carcinomatosis, since it is not totally soaked by the intraperitoneal chemotherapy solution.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Carcinoma / drug therapy. Colonic Neoplasms / pathology. Inguinal Canal. Peritoneal Neoplasms / drug therapy

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999360.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


86. Marin D, Catalano C, Baski M, Di Martino M, Geiger D, Di Giorgio A, Sibio S, Passariello R: 64-Section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings. Abdom Imaging; 2010 Dec;35(6):694-700
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 64-Section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings.
  • BACKGROUND: To prospectively investigate the diagnostic accuracy of a 64-section multi-detector row computed tomography (CT) for the detection of peritoneal metastases, with the use of surgery and histopathological findings as the reference standard.
  • METHODS: The study cohort comprised 18 patients with peritoneal carcinomatosis who underwent multiphasic CT with a 64-section CT, 0-119 days before cytoreductive surgery.
  • RESULTS: The overall sensitivity, specificity, positive, and negative predictive values of CT for the detection of peritoneal metastases were, respectively, 75% (93 of 124 lesions; confidence interval [CI] 68-84), 92% (118 of 128; CI 85-96), 90% (93 of 103; CI 83-95), and 79% (118 of 149; CI 72-86).
  • CONCLUSIONS: 64-Section CT with the addition of isotropic reformatted coronal and sagittal images is a very effective technique in the detection of peritoneal metastases of 0.5 cm in diameter or larger, although sensitivity decreases remarkably for lesions <0.5 cm in diameter.
  • [MeSH-major] Carcinoma / radiography. Peritoneal Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455272.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 17E17JBP8L / iomeprol; 3X9MR4N98U / Diatrizoate Meglumine; JR13W81H44 / Iopamidol
  •  go-up   go-down


87. Elias D, Benizri E, Pocard M, Ducreux M, Boige V, Lasser P: Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Surg Oncol; 2006 Aug;32(6):632-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer.
  • AIM: To report our experience of peritoneal carcinomatosis (PC) discovered during abdominal exploration in patients with liver metastases (LM).
  • Three patients developed a peritoneal recurrence and 13 had recurrence in the liver.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Adult. Catheter Ablation. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Multiple Primary. Prospective Studies. Risk Factors. Statistics, Nonparametric. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16621428.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Piso P, Glockzin G, von Breitenbuch P, Sulaiman T, Popp F, Dahlke M, Esquivel J, Schlitt HJ: Patient selection for a curative approach to carcinomatosis. Cancer J; 2009 May-Jun;15(3):236-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient selection for a curative approach to carcinomatosis.
  • There is an increasing evidence showing that in selected patients with peritoneal carcinomatosis cytoreductive surgery and hyperthermic intraperitoneal chemotherapy may improve survival.
  • Many selection criteria have to be assessed in each patient: performance status, comorbiditites, response to previous chemotherapies, histology grading, and presence of extra-abdominal or liver metastases, small bowel involvement, and tumor volume assessed by the peritoneal cancer index.
  • For appropriate selected patients with peritoneal carcinomatosis arising from appendiceal and colon cancer, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should be considered standard of care.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Patient Selection. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19556910.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down


89. Msika S, Gruden E, Sarnacki S, Orbach D, Philippe-Chomette P, Castel B, Sabaté JM, Flamant Y, Kianmanesh R: Cytoreductive surgery associated to hyperthermic intraperitoneal chemoperfusion for desmoplastic round small cell tumor with peritoneal carcinomatosis in young patients. J Pediatr Surg; 2010 Aug;45(8):1617-21
Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery associated to hyperthermic intraperitoneal chemoperfusion for desmoplastic round small cell tumor with peritoneal carcinomatosis in young patients.
  • PURPOSE: Desmoplastic round small cell tumor (DRSCT) is a rare intraabdominal mesenchymal tissue neoplasm in young patients and spreads through the abdominal cavity.
  • hyperthermic intraperitoneal chemotherapy (HIPEC) is considered as an additional strategy in the treatment of peritoneal carcinomatosis; for this reason, we planned to treat selected cases of children with DRSCT using CS and HIPEC.
  • METHODS: Peritoneal disease extension was evaluated according to Gilly classification.
  • CONCLUSIONS: Surgical cytoreduction and HIPEC provide a local alternative approach to systemic chemotherapy in the control of microscopic peritoneal disease in DRSCT, with an acceptable morbidity, and may be considered as a potential beneficial adjuvant waiting for a more specific targeted therapy against the fusion protein.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / surgery. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced / methods. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adolescent. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / surgery. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Injections, Intraperitoneal. Male. Palliative Care. Peritoneum / pathology. Peritoneum / surgery. Treatment Outcome. Tumor Burden / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20713209.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Minicozzi A, Borzellino G, Momo EN, Segattini C, Pitoni F, Steccanella F, De Manzoni G: [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up]. Ann Ital Chir; 2008 Jul-Aug;79(4):231-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
  • [Transliterated title] Trattamento della carcinosi peritoneale con chirurgia citoriduttiva e chemioipertermia intraperitoneale (IHPC): morbilità e mortalità postoperatorie e risultati a breve termine.
  • BACKGROUND: In order to treat the peritoneal carcinomatosis from abdominal neoplasms has been recently proposed complete peritonectomy associated with IntraPeritoneal Hyperthermic Chemotherapy (IHPC).
  • METHODS: Twenty-four patients with peritoneal carcinomatosis or positive cytology at peritoneal washing were treated in our Department from January 2005 to October 2007.
  • Primary tumor was ovarian carcinoma in ten patients: four cases presented peritoneal surface malignancies (PSM) after any time from hysteroadnexectomy related to primary tumor, six cases synchronous PSM.
  • Primary tumor was gastric cancer in seven patients: the peritoneal washing was positive in four cases and, during follow-up period after gastrectomy, other two cases presented PSM.
  • Primary tumor was pseudomixoma peritonei in four patients; cytoreductive surgery and IHPC was carried as first line therapy in only one patient.
  • IHPC was carried out through abdominopelvic cavity for 60 minutes using a closed abdomen technique.
  • RESULTS: The mean Peritoneal Cancer Index (PCI) was 14.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / therapy. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Length of Stay. Male. Middle Aged. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Peritoneum / surgery. Postoperative Complications. Time Factors. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19093624.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


91. Vaira M, Cioppa T, D'Amico S, de Marco G, D'Alessandro M, Fiorentini G, De Simone M: Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years. In Vivo; 2010 Jan-Feb;24(1):79-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.
  • INTRODUCTION: Peritoneal carcinomatosis (PC) is one of the routes of dissemination of abdominal neoplasms and is generally considered a lethal disease, with a poor prognosis by conventional chemotherapeutic treatments.
  • While systemic chemotherapy has little impact on the treatment of peritoneal disease, some centers have reported encouraging results with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • This approach is based on surgical cytoreduction of the primary tumour, peritonectomy (stripping of implants on the peritoneal surface) and HIPEC.
  • The rationale of this treatment, after macroscopic disease removal, is to obtain an elevated and persistent drug concentration in the peritoneal cavity, with limited systemic effects.
  • The specific features of both groups were considered for the survival curves and complication rates, with special reference to the peritoneal carcinomatosis index (PCI; range 0, absence of disease to 39) and completeness of cytoreduction score (CCR; 0, no residual tumor, to CCR 3, residual nodules greater than 25 mm).
  • [MeSH-major] Adenocarcinoma / therapy. Colonic Neoplasms / therapy. Hyperthermia, Induced. Peritoneal Neoplasms / therapy. Peritoneum / surgery. Pseudomyxoma Peritonei / therapy

  • Genetic Alliance. consumer health - TEN.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20133981.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


92. Roviello F, Marrelli D, Neri A, Cerretani D, de Manzoni G, Pedrazzani C, Cioppa T, Nastri G, Giorgi G, Pinto E: Treatment of peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP): postoperative outcome and risk factors for morbidity. World J Surg; 2006 Nov;30(11):2033-40; discussion 2041-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP): postoperative outcome and risk factors for morbidity.
  • BACKGROUND: Cytoreductive surgery with limited or extended peritonectomy associated with intraperitoneal hyperthermic chemoperfusion (IHCP) has been proposed for treatment of peritoneal carcinomatosis (PC) from abdominal neoplasms.
  • METHODS: Fifty-nine patients with PC from abdominal neoplasms underwent 61 treatments using this technique from January 2000 to August 2005.
  • In 16 patients with positive peritoneal cytology without macroscopic peritoneal disease, IHCP was performed in order to prevent peritoneal recurrence.
  • IHCP was carried out throughout the abdominopelvic cavity for 60 minutes using a closed abdomen technique.
  • Intra-abdominal temperature ranged between 41 degrees C and 43 degrees C; mitomycin C (25 mg/mq) and cisplatin (100 mg/mq) were the anticancer drugs generally used, and they were administered with a flow rate of 700-800 ml/minute.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / secondary. Carcinoma / therapy. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 2000 Jul;91(7):715-22 [10920279.001]
  • [Cites] Ann Surg Oncol. 2003 Oct;10(8):863-9 [14527903.001]
  • [Cites] J Surg Oncol. 2000 May;74(1):41-4 [10861608.001]
  • [Cites] Ann Surg Oncol. 2004 Apr;11(4):387-92 [15070598.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):884-91 [9041149.001]
  • [Cites] Arch Surg. 2004 Jan;139(1):20-6 [14718269.001]
  • [Cites] Am J Surg. 1999 Sep;178(3):256-62 [10527450.001]
  • [Cites] J Gastrointest Surg. 2004 May-Jun;8(4):454-63 [15120371.001]
  • [Cites] Dis Colon Rectum. 2000 Oct;43(10):1341-6; discussion 1347-8 [11052509.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):347-53 [15915368.001]
  • [Cites] Cancer Treat Res. 1996;81:149-68 [8834582.001]
  • [Cites] Surgery. 2002 May;131(5):521-8 [12019405.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1776-82 [11813623.001]
  • [Cites] Ann Surg Oncol. 2005 Nov;12(11):910-8 [16177862.001]
  • [Cites] J Surg Oncol. 2004 Feb;85(2):61-7 [14755505.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):212-22 [16432354.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):790-6 [10622509.001]
  • [Cites] Br J Surg. 2003 Sep;90(9):1113-9 [12945079.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):325-32 [15297169.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):508-13 [12794016.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):799-806 [12610177.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] World J Surg. 2004 Oct;28(10):1040-5 [15573262.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):219-28 [15050953.001]
  • [Cites] Cancer Treat Res. 1996;81:63-74 [8834576.001]
  • [Cites] J Chemother. 2005 Dec;17(6):668-73 [16433199.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1160-5 [12209247.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):18-22 [15612012.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):71-6 [11443611.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):247-55 [15650634.001]
  • [Cites] Br J Surg. 2005 Mar;92(3):370-5 [15739249.001]
  • [Cites] Eur J Cancer. 2001 May;37(8):979-84 [11334722.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):53-8 [15642426.001]
  • [Cites] Ann Surg Oncol. 2004 Feb;11(2):178-86 [14761921.001]
  • (PMID = 17006608.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


93. Whittington JK, Emerson JA, Satkus TM, Tyagi G, Barger A, Pinkerton ME: Exocrine pancreatic carcinoma and carcinomatosis with abdominal effusion containing mast cells in a ferret (Mustela putorius furo). Vet Clin North Am Exot Anim Pract; 2006 Sep;9(3):643-50
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exocrine pancreatic carcinoma and carcinomatosis with abdominal effusion containing mast cells in a ferret (Mustela putorius furo).
  • Transcoelomic metastasis and hemorrhagic abdominal effusion were secondary to the neoplasm.
  • The finding of mast cells in abdominal effusion, with a leukocyte component composed primarily of lymphocytes and lesser numbers of neutrophils and macrophages, is an atypical finding, never before reported in ferrets.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16931385.001).
  • [ISSN] 1094-9194
  • [Journal-full-title] The veterinary clinics of North America. Exotic animal practice
  • [ISO-abbreviation] Vet Clin North Am Exot Anim Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Rufián S, Muñoz-Casares FC, Briceño J, Díaz CJ, Rubio MJ, Ortega R, Ciria R, Morillo M, Aranda E, Muntané J, Pera C: Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol; 2006 Sep 15;94(4):316-24
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer.
  • BACKGROUND AND OBJECTIVES: Advanced ovarian cancer typically spreads in a diffuse intra-abdominal fashion.
  • METHODS: A series of patients (N = 33) diagnosed of peritoneal carcinomatosis for epithelial ovarian cancer (stage III) from January 1997 to December 2004 submitted to radical surgery-peritonectomy and HIIC with paclitaxel was included in this study; 19 primary ovarian cancer and 14 recurrent ovarian cancer.
  • Patients with optimal cytoreduction R0 obtained survival rates of 63% at 5 years in recurrent ovarian cancer and 60% in primary ovarian cancer, 71% and 63%, respectively with associated subtotal infra-abdominal peritonectomy, and even better results if negative lymph nodes.
  • CONCLUSIONS: Radical surgery-peritonectomy with HIIQ has been shown to be a surgical procedure with high tolerability, low morbimortality, enhanced survival, and prolonged disease-free interval in patients with peritoneal carcinomatosis so much for recurrent or primary ovarian cancer.
  • [MeSH-major] Intraoperative Care. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Peritoneum / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Cancer, Regional Perfusion. Disease-Free Survival. Female. Humans. Infusions, Parenteral. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16917864.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Piso P, Dahlke MH, Ghali N, Iesalnieks I, Loss M, Popp F, von Breitenbuch P, Agha A, Lang SA, Kullmann F, Schlitt HJ: Multimodality treatment of peritoneal carcinomatosis from colorectal cancer: first results of a new German centre for peritoneal surface malignancies. Int J Colorectal Dis; 2007 Nov;22(11):1295-300
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality treatment of peritoneal carcinomatosis from colorectal cancer: first results of a new German centre for peritoneal surface malignancies.
  • BACKGROUND: The presence of peritoneal carcinomatosis arising from colorectal cancer is associated with a poor prognosis.
  • MATERIALS AND METHODS: Thirty-two patients with peritoneal carcinomatosis were operated between April 2004 and June 2006 with the aim of complete macroscopical cytoreduction.
  • Complete cytoreduction may improve survival, particularly in well-selected patients having a low tumor volume and no extra-abdominal metastases.
  • [MeSH-major] Colorectal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10 ):1558-65 [15367418.001]
  • [Cites] Ann Surg Oncol. 2003 Oct;10(8):863-9 [14527903.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Ann Surg Oncol. 2005 Jan;12(1):65-71 [15827780.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):762-4 [12610170.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):403-7 [14735184.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] Int J Surg Investig. 2000;1(5):431-9 [11341599.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):212-22 [16432354.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):790-6 [10622509.001]
  • [Cites] Eur J Surg Oncol. 2005 Mar;31(2):147-52 [15698730.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):544-50 [16919104.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):106-18 [2826711.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):508-13 [12794016.001]
  • [Cites] Cancer. 1989 Jan 15;63(2):364-7 [2910444.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):128-33 [17072675.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):799-806 [12610177.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 May;57(5):703-8 [16096789.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):619-24 [16672186.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] Ann Oncol. 2006 Mar;17 (3):450-6 [16303861.001]
  • [Cites] Br J Surg. 2004 Jun;91(6):747-54 [15164446.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):71-6 [11443611.001]
  • [Cites] Eur J Cancer. 2001 May;37(8):979-84 [11334722.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):53-8 [15642426.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):155-62 [12620911.001]
  • [Cites] Ann Surg Oncol. 2004 Feb;11(2):178-86 [14761921.001]
  • [Cites] Oncologist. 2005 Feb;10(2):112-22 [15709213.001]
  • [Cites] Cancer Treat Res. 1996;82:359-74 [8849962.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):286-90 [11373107.001]
  • (PMID = 17458551.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Fushida S, Kinoshita J, Yagi Y, Funaki H, Kinami S, Ninomiya I, Fujimura T, Nishimura G, Kayahara M, Ohta T: Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Oncol Rep; 2008 May;19(5):1305-10
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study.
  • A total of 24 patients with peritoneal carcinomatosis of gastric cancer (10 preoperative, 7 postoperative and 7 recurrent) were enrolled in this study.
  • To measure the docetaxel concentration, blood and peritoneal fluid samples were collected 0.5, 1, 2, 3, 6 and 24 h after administering the drug to 15 patients.
  • At a docetaxel dosage of 60 mg/m(2) per week, the dose-limiting events of grade 3 abdominal pain and grade 3 diarrhea, which may be associated with local toxicity, occurred.
  • Peak concentrations of peritoneal fluid ranged from 24.5 to 68.7 microg/ml.
  • The mean ratio of the area under concentration (AUC) in the peritoneal fluid to the plasma concentration was 515.
  • The response rate of the preoperative IP docetaxel was 80% (4 CR, 4 PR, 1 NC and 1 PD), which was judged with laparoscopy and peritoneal lavage cytology.
  • The weekly IP docetaxel demonstrated a low toxicity and high efficacy for peritoneal carcinomatosis with dual anti-cancer effects via the peritoneal surface and capillary blood supply due to its unique pharmacokinetic property.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacokinetics. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy. Taxoids / administration & dosage. Taxoids / pharmacokinetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425392.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


97. Marcotte E, Sideris L, Drolet P, Mitchell A, Frenette S, Leblanc G, Leclerc YE, Dubé P: Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from appendix: preliminary results of a survival analysis. Ann Surg Oncol; 2008 Oct;15(10):2701-8
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from appendix: preliminary results of a survival analysis.
  • BACKGROUND: Peritoneal carcinomatosis (PC) arising from the appendix is a rare disease for which the long-term prognosis is poor.
  • The overall major (grade III-V/V) complication rate for treated patients was 39%, including intra-abdominal abscess (22%), hemorrhage (18%), and anastomotic leak (9%).
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Agents / therapeutic use. Appendiceal Neoplasms / drug therapy. Hyperthermia, Induced. Organoplatinum Compounds / therapeutic use. Peritoneal Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18654822.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


98. Colombo PE, Boustta M, Poujol S, Pinguet F, Rouanet P, Bressolle F, Vert M: Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration. Eur J Pharm Sci; 2007 May;31(1):43-52
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration.
  • Peritoneal spread is a common manifestation in ovarian and gastrointestinal cancer.
  • Peritoneal carcinomatosis was generated in BDIX rats (n=55) by i.p. injection of 2 million DHDK12 cells.
  • Free and polymer-bound DOX were assessed in plasma, peritoneal fluid, abdominal tissues and heart, 15 min, 2, 6, 24, 48 and 168 h after injection.
  • According to pharmacokinetic profiles, the peritoneal fluid areas under the concentration versus time curves (AUCs) were 2 and 2.6 times greater for the conjugates (P-DOX20 and P-DOX10, respectively) than for the free drug, respectively.
  • Conjugates crossed the peritoneal barrier slower than the free drug.
  • In contrast, significant retention and accumulation of the conjugates were found in abdominal organs, particularly in the tumor.
  • In conclusion, the conjugates have higher elimination half-lives than free DOX and were preferentially retained in abdominal organs and in the peritoneal carcinomatosis.
  • [MeSH-major] Carcinoma / metabolism. Doxorubicin / pharmacokinetics. Nylons / chemistry. Peritoneal Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17383164.001).
  • [ISSN] 0928-0987
  • [Journal-full-title] European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • [ISO-abbreviation] Eur J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Nylons; 0 / poly(lysine citramide imide); 80168379AG / Doxorubicin
  •  go-up   go-down


99. Rouers A, Laurent S, Detroz B, Meurisse M: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: higher complication rate for oxaliplatin compared to Mitomycin C. Acta Chir Belg; 2006 May-Jun;106(3):302-6
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: higher complication rate for oxaliplatin compared to Mitomycin C.
  • BACKGROUND: Peritoneal carcinomatosis (PC) from colo-rectal cancer carries a very poor prognosis with a mean and median overall survival times of 6.9 and 5.2 months.
  • RESULTS: All patients presented a Sugarbaker's Peritoneal Cancer index inferior to 15.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hyperthermia, Induced. Mitomycin / administration & dosage. Organoplatinum Compounds / administration & dosage. Peritoneal Neoplasms / therapy

  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910003.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 50SG953SK6 / Mitomycin
  •  go-up   go-down


100. Pfannenberg C, Königsrainer I, Aschoff P, Oksüz MO, Zieker D, Beckert S, Symons S, Nieselt K, Glatzle J, Weyhern CV, Brücher BL, Claussen CD, Königsrainer A: (18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol; 2009 May;16(5):1295-303
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
  • BACKGROUND: Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with significantly longer survival in patients with peritoneal carcinomatosis (PC).
  • So far, no morphological imaging method has proven to accurately assess the intra-abdominal tumor spread.
  • In a retrospective analysis PET, CT, and fused PET/CT were separately and blindly reviewed for the extent of peritoneal involvement using the Peritoneal Cancer Index (PCI).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Peritoneal Neoplasms / radionuclide imaging. Peritoneal Neoplasms / therapy. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Chemotherapy, Cancer, Regional Perfusion. Combined Modality Therapy. Female. Fluorodeoxyglucose F18. Humans. Hyperthermia, Induced. Infusions, Parenteral. Male. Middle Aged. Neoplasm Staging. Patient Selection. Predictive Value of Tests. Radiopharmaceuticals. Surgical Procedures, Operative. Tumor Burden

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19252950.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down






Advertisement